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ABSTRACT 
Sulforaphane (SFN) is an isothiocyanate found mostly after consumption of broccoli, 
but also other cruciferous vegetables such as cauliflower or cabbage. 
Isothiocyanates have been researched for over 20 years in the field of cancer. They 
show many different bioactivities, of which the majority are positively associated 
with cell health and are possibly collectively responsible for protective effects of SFN 
against toxin-induced cell death. 
This study aims to investigate the bioactivities of SFN on neuronal cells. PC-12 and 
SH-SY5Y cells were used to resemble neuronal-like systems to research especially 
autophagy as well as nuclear factor E2-related factor 2 (Nrf2) and how these 
pathways might influence neuroprotective abilities of SFN. 
Basal assessments confirmed that SFN can induce Nrf2-driven phase II enzymes, as 
determined by qPCR as well as immunoblotting. The elevation of the main 
autophagy marker light chain 3-II (LC3-II) by SFN could be observed dose-
dependently at protein level. In addition, SFN pre-treatment provided statistically 
significant cytoprotection against H2O2- and 6-hydroxydopamine- (6-OHDA) 
induced cell death.  
Further, DJ-1, a multifunctional protein, was selected for investigation with SFN, since 
it is highly implicated with neuronal cell health. SFN induced DJ-1 protein levels 
dose-dependently. In addition, tunicamycin-induced ER-stress was significantly 
reduced by SFN, as shown using the ER-stress marker CHOP on protein and RNA 
levels.  
To intensify the research of SFN and autophagy, primary neuronal cells (PNCs) were 
developed from embryos from Atg16L1 wild type and knock out (KO) mice. Atg16L1 
is a protein necessary for autophagosome formation. Immunostainings assessed 
that autophagy was indeed fully supressed in KO cells. Preliminary results suggest 
that autophagy is involved in the neuroprotective effects of SFN. 
Conclusively, SFN was able to significantly protect all neuronal cells investigated 
from H2O2- or 6-OHDA-induced cell death. SFN’s ability to activate autophagy as 
well as DJ-1 may contribute to its protective effects. 
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1 INTRODUCTION 
1.1 SULFORAPHANE 
1.1.1  GENERAL INTRODUCTION 
Since the 1990s, epidemiological and human intervention studies have suggested 
an inverse association between the intake of plant foods like turmeric, garlic or 
cabbage, and risk of cancer or a number of other chronic diseases (Surh 2003; 
Ferrari et al. 2010). A variety of phytochemicals, i.e. chemicals naturally occurring in 
plants, have been shown to  enhance the metabolism and elimination of 
xenobiotics, like drugs, pesticides or carcinogens, thus antagonising their 
carcinogenicity (Zhang et al. 1992). 
Cruciferous vegetables (CV) of the family Brassicaceae have become a research 
area of particular interest, since they have been associated with a reduced risk of 
development of a range of cancers (Verhoeven et al. 1996; Talalay & Fahey 2001). 
Such vegetables include broccoli, cabbage, kale, Brussels sprouts, cauliflower, 
mustard, wasabi, cress and radish (Verkerk et al. 2009; Fahey et al. 2001; Fimognari 
et al. 2008). They contain many beneficial dietary compounds, such as vitamin C, 
carotenoids, fibre, flavonoids and glucosinolates (McNaughton & Marks 2003). The 
sulphur containing glucosinolates are present in almost every CV and are 
responsible for their distinct aroma (Fahey et al. 2001; Vermeulen et al. 2006). 
Anticarcinogenic properties of CVs were first reported in the 1980s (Albert-Puleo 
1983). A decade later, sulforaphane (SFN) was identified as the chemical primarily 
responsible for the bioactivity of broccoli, leading to further research in this area 
(Dinkova-Kostova & Kostov 2012; Zhang et al. 1994; Zhang et al. 1992). Studies on 
the molecular targets of SFN have led to a greater understanding of its mechanism 
of action. SFN shows a range of potential therapeutic effects and therefore is a 
potential candidate for therapeutic use in humans (Guerrero-Beltrán et al. 2010).  
One CV can contain several glucosinolates, some with “anti-nutritional” properties, 
such that their inclusion in the diet can reduce the nutritional value of a meal 
(Griffiths et al. 1998). For example, the hydrolysis of β-hydroxyalkenyl glucosinolates 
creates β-hydroxyalkenyl isothiocyanates, which can further cyclise to oxazolidine-
2-thiones - which may have goitrogenic effects  (Fahey et al. 2001).  Conversely,  
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“nutritional” or “functional” glucosinolates may have therapeutic and prophylactic 
properties (Fahey et al. 2001). Over 120 different glucosinolates have been 
identified in cruciferous plants, however few occur in dietary crucifers (Juge et al. 
2007). Glucosinolates are β-thioglucoside N-hydroxysulfates with a side chain (R) 
and a sulphur-linked β-D-glucopyranose moiety (Fahey et al. 2001). 
Glucosinolates, as opposed to their metabolites, are mostly biologically inactive 
(Vermeulen et al. 2006). In plants, they are accumulated in vacuoles in close 
proximity to myrosin cells, which are separate cells with vacuoles containing the 
enzyme myrosinase (Kissen et al. 2009).  A natural defence mechanism is activated 
by cutting, grinding or chewing of plant tissue, when myrosinase is released and 
hydrolyses the glucosinolates into isothiocyanates (ITCs) and other metabolites 
(Fimognari et al. 2008; Kissen et al. 2009). ITCs are considered the major metabolite 
at pH 5-8, whilst at pH 2-5 in the presence of Fe2+ or guided by the heat-sensitive 
epithiospecifier protein (ESP) mostly nitriles and elemental sulphur are produced, 
and at pH >8 thiocyanates are generated (Figure 1) (Fimognari et al. 2008; Grubb 
& Abel 2006; Matusheski et al. 2004).  
 
 
Figure 1: Metabolism of glucosinolates to their break down products. 
Myrosinase catalyses the hydrolysis of glucosinolates to different end products, 
such as isothiocyanates, nitriles, or thiocyanates; depending on the reaction 
conditions. Adapted from (Dinkova-Kostova & Kostov 2012). 
Cooking vegetables or applying pressure, which is often performed to inhibit activity 
of microorganisms and spoilage enzymes and therefore enhance storage life 
(preferably without affecting the quality of the product),  inactivates myrosinase 
(Ghawi et al. 2012). Exposure to temperatures between 35°C and 70°C, for a 
duration as short as three minutes, has been shown to reduce myrosinase activity 
considerably in broccoli (Ludikhuyze et al. 1999; Oliviero et al. 2014) or green 
cabbage (Ghawi et al. 2012). High pressure-thermal inactivation has presented 
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synergistic as well as antagonistic effects  at pressures below 200MPa, which may 
also differ between Brassica species (Ghawi et al. 2012). 
In humans, glucosinolates are metabolised to ITCs by the bacterial flora of the 
gastrointestinal tract, although their activity is considerably less than that of 
myrosinase (Fahey et al. 2001; Shapiro et al. 2001; Lampe & Peterson 2002). After 
absorption, ITCs are conjugated to glutathione and are eliminated through the 
mercapturic acid pathway (Figure 2; shown for the example of SFN) (Vermeulen et 
al. 2008).   
 
Figure 2: The mercapturic acid pathway shown for SFN 
GST, glutathione-S-transferase  
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1.1.2  SULFORAPHANE AND ITS METABOLISM IN HUMANS 
SFN [1-isothiocyanato-4-(methylsulfinyl)-butane] is the primary breakdown product 
of the glucosinolate glucoraphanin, which is found in cruciferous vegetables such 
as broccoli, cabbage, kohl rabi and cauliflower (Figure 3) (Juge et al. 2007). 
SFN is subject to metabolism by glutathione γ-glutamyltranspeptidase, 
cysteinylglycinase and N-acetyltransferase to form mercapturic acid (Figure 2) 
(Shapiro et al. 2001). This compound can be easily measured in urine by HPLC (High 
performance liquid chromatography) and UV spectroscopy after 
cyclocondensation with 1,2-benzenedithiol to form 1,3-benzodithiole-2-thione, and 
therefore mercapturic acid serves as a reliable biomarker for the measurement of 
cruciferous vegetable intake (Fimognari et al. 2008). 
 
Figure 3: Chemical structures of glucoraphanin and sulforaphane. 
 
1.1.3  BIOAVAILABILITY OF SULFORAPHANE 
Ye et al (2002) performed the first human study of bioavailability of SFN, in which 
four volunteers consumed a single dose of 200µmol of ITCs obtained from broccoli 
sprouts. A peak concentration of 0.9-2.3µmol/l ITCs was detected in plasma, serum 
and erythrocytes 1 hour after consumption, with a half-life of 1.8h. At 8h, elimination 
of 58% of the dose was detected, whilst clearance in urine was 369±53ml/min, 
indicating active renal tubular secretion (Ye et al. 2002). During this study, a reliable 
and sensitive method to determine ITC levels in plasma and blood was created (Ye 
et al. 2002). All metabolites generated during the mercapturic acid pathway (Figure 
2) belong to the class of dithiocarbamates (DTC), which can be quantified as their 
cyclocondensation product with 1,2-benzenedithiol by spectroscopy. As ITCs are 
rapidly and completely converted to DTCs in human tissues, this can be a very useful 
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analytical method, although it does not distinguish between ITCs and DTCs (Ye et 
al. 2002). 
A more recent human randomised blinded cross-over study compared the 
bioavailability of broccoli sprouts and a broccoli supplement (Clarke et al. 2011). 
Consumption of six supplement pills (containing 121µmol glucoraphanin) by study 
subjects produced peak plasma concentrations of total SFN metabolites after 6 
hours, whilst intake of 40g of broccoli sprouts (containing 150µmol glucoraphanin) 
resulted in a peak of total SFN metabolites after 3 hours and at a 7-fold higher 
concentration than the supplement pills, which did not contain any myrosinase.  
Urinary excretion of SFN metabolites following consumption of broccoli sprouts 
peaked between 3 and 6 hours, in contrast to a delayed excretion of later than 6 
hours following consumption of the supplements (Clarke et al. 2011). 
A number of studies in humans have shown significant differences in bioavailability, 
absorption and excretion kinetics depending on the cooking or storage method of 
the vegetables. Vermeulen et al (2008) observed a peak plasma concentration of 
SFN from consumption of 200g raw broccoli after 1.6 hours, compared to a peak 
after 6 hours following intake of cooked broccoli. The amount of ITCs derived from 
cooked vegetables was 2-10 times lower than from raw vegetables – as long as the 
raw vegetables were fully chewed. However, even after consumption of raw 
broccoli, only 37% of sulforaphane mercapturic acid was recovered in urine. This 
may be because glucoraphanin was not fully converted to SFN, or because SFN 
was not fully absorbed from the gut (Vermeulen et al. 2006; Vermeulen et al. 2008).  
The effect of cooking time and type of cruciferous vegetables on SFN bioavailability 
has been investigated by several research groups, showing that blanching or short 
microwaving of ~2 minutes is to be favoured over cooking (Holst & Williamson 2004; 
Rungapamestry et al. 2007; Saha et al. 2012). Saha et al (2012) also presented a 
comparison between broccoli soup prepared from fresh or frozen broccoli, in which 
the bioavailability of SFN was tenfold higher for soups made from the former as 
compared to the latter. 
Inter-individual variation in SFN bioavailability has been observed in a number of 
studies, and can be explained by a polymorphism in the GSTM1 gene, which results 
in lack of GSTM1-1 protein (Holst & Williamson 2004). A human cross-over study on a 
single meal of broccoli investigated the pharmacokinetics involved in this 
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polymorphism and found that GSTM1-null subjects excreted more SFN over 24 hours 
in urine and plasma, and at a greater rate, than GSTM1-positive individuals (Gasper 
et al. 2005). This lead to the assumption that GSTM1-positive persons benefit from 
the consumption of CVs more. 
However, contrary to these findings, a nested case-control study in a female 
Shanghai-based cohort investigated the association between urinary 
isothiocyanate concentrations and colorectal cancer risk with the potential 
modifying effect of GST genotypes (Yang et al. 2010). Apart from finding an inverse 
association between urinary ITCs and colorectal cancer risk, this study also 
demonstrated that ITCs had protective effects in GSTM1-null patients. Urinary ITC 
concentration was lower in GSTM1-null women than in women who carried this 
gene, suggesting that the metabolic clearance rate varies by GST genotype. This 
supports the theory that individuals with GST deletion may be less efficient in 
metabolising and eliminating ITCs, and thus can be exposed to higher 
concentrations of ITCs, with an increased benefit from consumption of cruciferous 
vegetables in terms of their health-promoting effects (Lampe & Peterson 2002; Holst 
& Williamson 2004; Yang et al. 2010). The difference found in metabolic clearance 
rate and thus the different theories on GSTM1 being beneficial in reducing cancer 
risk can amount to the Chinese study being a population study, compared to a 
feeding study. A prolonged feeding study might reflect habitual dietary intake 
among populations that consume CVs routinely (Lampe 2009). These different 
results indicate that further understanding is necessary on how genotype influences 
the disposition of ITCs. 
Of interest, more recent human bioavailability studies of SFN following r broccoli 
consumption have showed a bioconversion of SFN into erucin (ERN), another 
isothiocyanate (Vermeulen et al. 2006; Clarke et al. 2011; Tarozzi et al. 2013). A 
mouse study found this conversion to be tissue dependent, with a higher ratio of 
ERN in the liver, kidney and bladder, even when feeding SFN alone (Bricker et al. 
2014). Although investigations into possible differences into the bioactivities of SFN 
and ERN exist, it is still not clear whether this conversion is important for the beneficial 
effects of glucosinolates (Jana Jakubikova et al. 2005; Tarozzi et al. 2013; Bricker et 
al. 2014).                                                                             .
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1.1.4  BIOACTIVITY OF SULFORAPHANE 
The bioactivity of SFN has been investigated in numerous studies, as outlined in the 
following sections.  To date, induction of phase II enzymes by SFN is the most 
comprehensively researched effect of this compound. 
A) Effects on detoxification enzymes.  
Phase I enzymes – modification 
Cytochrome P-450 (CYP) enzymes (phase I enzymes) are essential components 
in the metabolic pathways of numerous endogenous compounds, but may also 
cause the activation of carcinogens (Skupinska et al. 2009). SFN is known to inhibit 
several CYP enzymes such as CYP1A1, 1A2, 2B1/2, 2E1 and 3A4. CYP 3A4 is 
among the most important enzymes of the P-450 family, as it contributes to the 
metabolism of over 50% of clinically used drugs and xenobiotics (Gross-
Steinmeyer et al. 2010). The nuclear hormone receptor, steroid and xenobiotic 
receptor (SXR), is one of the most important mediators of CYP 3A4 expression. SFN 
has been shown to inhibit SXR-co-activator interactions by binding directly to SXR 
(Fimognari et al. 2008). 
Phase II enzymes – conjugation 
As noted, the effect of SFN on phase II enzymes has been extensively studied. 
SFN is known to induce genes encoding phase II enzymes, which metabolise a 
variety of reactive carcinogens, mutagens and other toxins. These genes include 
those encoding NAD(P)H:quinone oxidoreductase (NQO1), GSTs, uridine 5-
diphosphate-glucuronosyl transferase, ferritin, γ-glutamate-cysteine ligase, 
epoxide hydrolase and catalase. An increase in levels of the NR-E2-related factor 
2 (Nrf2) transcription factor activity is thought to be responsible for induction of 
these genes (Fimognari et al. 2008). Under normal conditions, Nrf2 is bound tightly 
to the Kelch ECH associated protein 1 (Keap1), which results in ubiquitination and 
proteasomal degradation of Nrf2 (James et al. 2012). ITCs can react with the 
sulfhydryl groups of Keap1, liberating Nrf2, which then translocates into the 
nucleus and binds to the antioxidant response element (ARE), activating the 
transcription of phase II enzymes (Figure 4; a more detailed graph is presented in 
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Figure 13, p.44) (James et al. 2012; Dinkova-Kostova et al. 2002; Dinkova-Kostova 
& Talalay 2008). 
Dinkova-Kostova et al (2007) have investigated the relationship between SFN 
and phase II enzymes in mouse and human skin after topical application of 
broccoli sprout extract, and detected an induction of NQO1 in humans and of 
NQO1, GST A1 and heme oxygenase (HO-1) in mice. Statistical analysis 
demonstrated increases of 1.5 – and 2.7-fold in mouse and 1.5- and 4.5-fold in 
humans after application of single and multiple doses (Dinkova-Kostova & 
Talalay 2008). An induction of phase II enzymes like transferases and catalases 
could also be found in liver, prostate, kidney and colon (Fimognari et al. 2008; 
Cheung & Kong 2009). 
A study by Zhao et al. (2007) has investigated the protective effects of SFN upon 
the permeability of the blood brain barrier (BBB). Using a rodent model of brain 
injury, it was demonstrated that through activation of Nrf2 regulated genes such 
as like GST and HO-1, the vulnerability of the BBB to injury is reduced by SFN. The 
loss of endothelial cell markers as well as tight junction proteins, which are the 
 
Figure 4: Overview of modulation of  Keap1/Nrf2 by SFN 
By modulating Keap1 via their sulfhydryl groups, Nrf2 is released from Keap 1 
and translocates into the nucleus, where it binds to the ARE to activate the 
transcription of phase II enzymes.  Nrf2, NR-E2-related factor 2; Keap1, Kelch 
ECH associated protein 1; ARE, antioxidant response element; sMaf, small 
musculoaponerotic fibrosarcoma; GST, glutathione-S-transferase; HO-1, 
hemeoxygenase-1; NQO1, NAD(P)H:quinone oxidoreductase. 
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two most critical components of the BBB, could be reduced by administration of 
SFN after brain injury. 
SFN has been found to protect primary cultures of mouse cortical neurons from 
5-S-cysteinyl-dopamine-induced neurotoxicity. Concentrations between 0.01-
1µM SFN modulated the Keap1/Nrf2 pathway, leading to an increased 
expression of GST, TR-1 and NAD(P)H oxidoreductase (Vauzour et al. 2010). 
Phase III transporters – transport and excretion 
Phase III transporters belong to a family of ATP-binding cassette membrane 
transport proteins which are also called multidrug resistance proteins. As they 
transport not only unmetabolised drugs and endogenous substrates, but also 
products of phase I and II drug metabolism, they have been termed phase III of 
the detoxification system (Harris & Jeffery 2008). SFN is known to regulate the 
phase III transporters P-gp (P-glycoprotein) and MRP (multidrug resistance protein 
1), which contribute, in part, to the detoxification of many xenobiotics (Fimognari 
et al. 2008; Harris & Jeffery 2008). 
B) Cell cycle 
Cell division is classified into two stages: mitosis (M) and interphase, which itself 
can be further divided into G1, S and G2 phases. The cell cycle is controlled by 
several mechanisms to ensure correct cell division (Vermeulen et al. 2003). 
Impairment of these mechanisms can lead to disease, thus the cell cycle has 
been investigated in relation to cancer, as alterations in genetic control may 
lead to unrestrained cell proliferation (Vermeulen et al. 2003). This mechanism 
represents an important target in the treatment of cancer as well as other 
diseases. 
Research on SFN in the cell cycle has shown mostly induction of G1 or G2/M cell 
cycle arrest (Parnaud et al. 2004; Pledgie-Tracy et al. 2007; Shan et al. 2006; J 
Jakubikova et al. 2005), but in some cell lines S-phase induction has also been 
reported. A study investigating the effects of broccoli sprout extract on human 
bladder cancer UM-UC-3 cells has shown that 7.5-30µM extract leads to arrest in 
both S and G2/M phases (Tang et al. 2006). 
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C) Apoptosis 
Lower concentrations of SFN have been shown to induce early apoptosis in 
human bladder cancer T24 cells (Shan et al. 2006). Pledgie-Tracy et al (2007) 
have reported that SFN induces apoptotic cell death in breast cancer cells; and 
studies in blood, brain, colon, ovary, pancreas, prostate and skin cancer cell lines 
have documented the ability of SFN to induce apoptosis (Zhang & Tang 2007). 
The pre-treatment of SH-SY5Y cells, a neuronal-like cell line derived from a human 
neuroblastoma, with SFN before the addition of 6-hydroxydopamine (6-OHDA) 
resulted in a reduction in several apoptotic events such as  mitochondrial 
depolarisation, caspase 3 and 9 activation and DNA fragmentation, as well as 
necrosis (Tarozzi et al. 2009). In healthy SH-SY5Y cells, SFN was able also prevent 
apoptosis. 
D) Autophagy 
Autophagy is a pathway mainly activated through starvation to degrade 
unnecessary cell organelles and consequently replenish the cells with amino 
acids and other small molecules. It is an important mechanism for cell 
homeostasis, and impaired autophagy is linked to many illnesses including 
neurodegenerative diseases (Rubinsztein et al. 2005; Pan et al. 2008). A study in 
2006 first reported that SFN could induce autophagy as a human defence 
mechanism against SFN-induced apoptosis (Herman-Antosiewicz et al. 2006). This 
research was conducted using the human prostate cancer cell lines PC-3 and 
LNCaP. Subsequently, Nishikawa et al (2010) observed induction of autophagy 
after treatment with SFN,  in the human colon cancer cell line WiDr. 
Autophagy is discussed in more detail in Chapter 1.4. 
E) NF-κB pathway 
The nuclear factor kappa B (NF-κB) pathway has been linked to inflammation, 
cancer cell survival and progression, as this transcription factor binds to the 
promoter of many pro-inflammatory genes such as those encoding 
cyclooxygenase (COX-2), tumour necrosis factor α (TNF-α) and inducible nitric 
oxide synthase (iNOS) (Cheung et al. 2009). COX-2 is the key enzyme in the 
production of prostaglandins from arachidonic acid, and prostaglandins are 
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central mediators of inflammation (Tsatsanis et al. 2006). Over-expression of COX-
2 too has been associated with human bladder cancer (Shan et al. 2009).  Shan 
et al (2009) reported that SFN inhibits the binding of NF-κB to the COX-2 promoter, 
leading to down-regulation of COX-2 expression in human bladder cancer T24 
cells. The exact mechanism by which SFN inhibits the pathway is not yet 
established, but it may block the “inhibitor of κB”-kinase (IκK), which is an 
upstream enzyme of   NFκB (Cheung & Kong 2009). 
F) Cell proliferation and mitosis 
The potential beneficial effects of SFN upon reproduction of viable cells has also 
been the focus of several studies. Zanichelli et al (2011) observed increased 
proliferation in human mesenchymal stem cells after intake of low doses (0.25µM 
and 1µM) of R-SFN. However, higher doses (5µM and 20µM SFN) had a cytotoxic 
effect. In the breast cancer cell lines MCF7 and SUM159, SFN elicited 
antiproliferative effects with IC50 (half maximal inhibitory concentration) values of 
16µM and 10µM SFN respectively (Li et al. 2010). Azarenko et al (2008) have 
discovered that the mechanism by which SFN elicits inhibition of mitosis is 
effective suppression of microtubules dynamics and stabilisation of microtubules.   
G) Dopaminergic cells 
Han et al (2007) demonstrated that SFN can protect dopaminergic (DAergic) 
cells from the cytotoxicity of tetrahydrobiopterin (BH4) and 6-OHDA, both 
compounds known to generate oxidative stress and cause selective death of 
DAergic cells. SFN does not protect DAergic cells from MPP+-induced toxicity. 
MPP+, unlike the compounds mentioned above, does not produce DA quinone 
as its principle mechanism of toxicity. This suggests that SFN may  elicit  a 
protective effect in DA cells from   toxicity resulting from quinone generation (Han 
et al. 2007). 
H) Serotonin Receptor 
Mastrangelo et al (2008) reported that SFN at 5, 10 and 20µM dose-dependently 
down-regulated the serotonin receptors 5HT1A, 5HT2C and 5HT3A in Caco-2 cells 
after exposure to SFN for 48 hours. In contrast, nAChR (Nicotinic acetylcholine 
receptor) was up-regulated after exposure to SFN. Previous studies have shown 
that induction of neurotransmitter receptors plays a role in the progression of 
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colon cancer cells like HT-29 (Mastrangelo et al. 2008). To our knowledge, only 
one study has explored the interaction between SFN and serotonin. 
I) Antibiotic activity against Helicobacter pylori 
Several researchers have documented activity of SFN as an antibacterial agent 
against Helicobacter pylori (Fahey et al. 2002; Haristoy et al. 2003; Yanaka et al. 
2009). Studies in mouse models as well as human interventions have shown SFN 
to have both a direct antibacterial effect on H. pylori and an indirect, systemic 
effect by accessing the cytoprotective phase II response via Nrf2, as explained 
above (Yanaka et al. 2009). Direct effects in humans were explained by the 
activity of both glucoraphanin and its bioactive metabolite SFN on the gastric 
membrane mucosa, thus reducing gastritis. Since H. pylori  has been linked to the 
progression of stomach cancer, the findings support the suggestion that SFN can 
act as a dietary prophylactic agent against the development human gastric 
cancer (Yanaka et al. 2009). 
Thus, SFN is a powerful phytochemical that can activate multiple molecular targets 
resulting in detoxification of a variety of carcinogens. SFN may also act to protect 
cells from neurotoxins, demonstrate antibiotic activity, and induce early apoptosis 
as well as autophagy (Figure 5). However, these effects are not yet fully understood, 
and to date have been subject to limited investigation in neuronal cells. Hence, the 
research focus of this study was neuronal cells. 
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Figure 5: Overview of bioactivity of SFN 
This graph highlights pathways which are influenced by SFN. Green 
arrows indicate an upregulation, while a red arrow shows a 
decrease.  
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1.2 NEURODEGENERATIVE DISEASES 
Neuronal cells are electrically excitable cells that transmits information through 
electrical and chemical signals. They are the most important element of the 
central nervous system (Loeffler G. 2003). 
1.2.1  CENTRAL NERVOUS SYSTEM  
The central nervous system (CNS) is responsible for converting external stimuli as 
registered by the sensory organs into sensation, the control of motor skills,  as well as 
the coordination of many vital functions (Loeffler G. 2003). It consists of the brain 
and the spinal cord.   
The BBB isolates the CNS from the blood stream and thus from the rest of the body, 
and protects the nervous system from fluctuations in metabolism as well as from 
exposure to toxins. The major components of the BBB are a layer of brain capillary 
endothelial cells and the contiguous tight junctions between them (Zhao et al. 
2007). Gases like O2 and CO2 and a wide range of lipid-soluble molecules (subject 
to factors such as molecular weight or number of rotatable bonds) can passively 
diffuse across the BBB (Abbott et al. 2010). Other essential substances such as amino 
acids must pass through this barrier by active  transport (Loeffler G. 2003).  
The integrity of the BBB is essential for maintaining brain function and homeostasis 
(Zhao et al. 2007). Several diseases such as stroke, epilepsy, brain tumours, and 
neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease 
(PD) have been associated with a dysfunctional BBB (Abbott et al. 2010). As noted 
above, SFN has been reported to protect endothelial cells of the BBB by increasing 
expression of Nrf2-regulated genes including HO-1 and GST (Zhao et al. 2007). 
In order to elicit possible protective effects in neurodegenerative conditions or 
improve brain function, SFN should penetrate the BBB and accumulate in the CNS. 
According to Benedict et al. (2012) SFN is able to pass through the BBB in rats. This 
was also observed in various other animal models (Tarozzi et al. 2013).  
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1.2.2  NEURODEGENERATIVE DISEASES 
Neurodegenerative diseases (NDs) can be characterised by a progressive loss of 
neuronal cell function or even cell death. As NDs are age-related and the elderly 
proportion of the population in developed countries is growing, the reported 
incidence of NDs is also increasing (Melo et al. 2011). Although many theories have 
been proposed, the underlying mechanisms of neurodegeneration remain 
unknown.  Most neurodegenerative disorders are late-onset, progressing slowly, and 
clinical research suggests they have long asymptomatic phases before the first signs 
of illness appear (Golde 2009). 
Parkinson’s Disease (PD) is mainly characterised by a loss of dopaminergic cells in 
the substantia nigra, which is located in the midbrain and involved in the regulation 
of movement, but also by accumulation of the α-synuclein protein in specific brain 
regions (Lees et al. 2009). Through the reduction in dopamine production – typically 
a PD patient has lost 80% of dopamine-producing cells – the motor nervous system 
is unable to control coordination and movement (Zlokovic 2008). Symptoms of PD 
include muscle tremor, stiffness, and slow movement or inability to move, together 
with psychological symptoms such as insomnia, depression, and fatigue (Lees et al. 
2009). PD is the second most common neurodegenerative disease, affecting 
approximately 6.3 million people worldwide and 120,000 in the UK 
(www.parkinsonsawareness.eu.com 2012; European Brain Council 2011). The age 
of onset of PD is usually over 60 years, but 10% of patients are diagnosed in their 40s 
or earlier (EuroPa 2014; Lees et al. 2009). Although most cases are sporadic, several 
genes have been linked to familial PD, such as the genes encoding Parkin, α-
synuclein, PINK1, DJ-1 and LRRK-2 (Lees et al. 2009). To date, no cure is available, 
although levodopa and dopamine agonists can reduce symptoms of PD by 
replacing the lost dopamine. Dopamine itself cannot be used, since it cannot pass 
the BBB (Loeffler G. 2003). 
In Alzheimer’s Disease (AD), the synthesis of acetylcholine is reduced. AD is the most 
common form of dementia. Long-term memory loss, confusion and mood swings 
are the classic symptoms of AD. In 2011, over 600,000 cases were estimated in 
England (alzheimers.org.uk 2012). More than 25% of the population over 85 years 
old are believed to suffer from AD in Germany (Loeffler G. 2003). AD is typified by 
two classic changes within the brain; firstly an extraneuronal accumulation of 
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amyloid plaques consisting of β-amyloid peptide, and secondly intraneuronal 
deposits of neurofibrillary tangles composed of hyperphosphorylated tau protein 
(Lee et al. 2013). Although hardly distinguishable from sporadic AD in terms of 
phenotype and clinical manifestation, 5-10% of AD cases have been estimated to 
be genetic (Selkoe 2001). AD  has been described as a multifactorial disease 
involving a variety of molecular triggers, including synaptic failure, mitochondrial 
dysfunction, inflammation, loss of calcium regulation and faulty cholesterol 
metabolism (Querfurt & LaFerla 2010). As with PD there is currently no curative 
therapy for AD, but acetylcholinesterase inhibitors such as donezepil or 
galantamine can retard the degenerative process. 
Huntington’s Disease (HD) is a neurodegenerative disease resulting from  mutation 
of the “Huntington’s gene”, which encodes the protein huntingtin (Ross & Tabrizi 
2010). According to the Huntington’s Disease Association, over 6,000 patients in the 
UK have reported symptoms of HD (www.nhs.uk 2011). HD patients display random, 
uncontrollable movements (chorea), abnormal posture and difficulties in chewing 
and speaking. The symptoms usually develop in people between 30-50 years of 
age, progressing to death within 15-20 years (Walker 2007; Ross & Tabrizi 2010; 
Krobitsch & Kazantsev 2011). At present only symptomatic drug therapy is available. 
The chorea can be reduced by benzodiazepines, neuroleptics and tetrabenazine, 
while rigidity can be alleviated by levodopa or baclofen. However, use of all of 
these medications may also result in severe side effects (Ross & Tabrizi 2010). 
Research is therefore focusing on finding suitable biomarkers to investigate early-
intervention strategies (Walker 2007). 
One of the most common neuromuscular diseases is Amyotrophic Lateral Sclerosis 
(ALS), also known as Lou Gehrig’s disease or Motor Neuron Disease (MND). ALS 
results from death of both upper and lower motor neurons. Muscle weakness and 
atrophy spread throughout the body, eventually affecting moving, swallowing and 
forming words. Worldwide, between 0.4 and 1.8 persons per 100 000 population 
develop ALS, although Guam is a notable exception with a 50 times higher 
prevalence (Europe 2014). The cause for this higher incidence of ALS may be 
environmental, as a seed of plant Cycas cicinalis L. is a traditional source of food 
and medicine in this country, but also contains a potent neurotoxin (Spencer et al. 
1987). The age of onset of ALS is 40 to 70 years, with an average age of 55 at 
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diagnosis (Europe 2014). The drug riluzole reduces damage to motor neurons by 
activating the glutamate transporter and to date is the only treatment known to 
improve survival; however, it cannot repair damage already sustained by motor 
neurons (Europe 2014). 
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1.2.3  NEUROTOXICITY AND NEUROPROTECTION 
As there are no known curative treatments for neurodegenerative diseases, current 
scientific research is focussed on investigating mechanisms of neuroprotection as 
well as neurotoxicity. However, without knowing the underlying mechanisms of cell 
death in NDs, it is challenging to establish targets for treatment (Melo et al. 2011). 
Dietary phytochemicals may represent a potential source of neuroprotective 
agents. Melo et al. (2011) have reviewed the role of oxidative stress in NDs, and 
discussed recent developments including clinical trials undertaken with several 
potential neuroprotective agents such as antioxidants, metal chelators and 
antiglutamatergic agents. Selegiline and rasagiline, which are selective 
monoamino oxidase B (MAO B) inhibitors, are the most promising drugs in PD tested 
in clinical trials, (Melo et al. 2011). 
SFN has been shown to have neuroprotective effects in a number of animal models 
and in in vitro studies, using 6-OHDA and H2O2 as toxins to induce neuronal cell 
death (Guerrero-Beltrán et al. 2010).  Most of the studies in that review observed a 
relationship between the induction of Nrf2 and cell protection (Innamorato et al. 
2008; Soane et al. 2010; Vauzour et al. 2010). 
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1.3 NEURONAL CELL LINES 
As neurodegenerative diseases are increasing in prevalence in the developed 
world, with no effective curative treatments available, animal and in vitro studies 
are important to gain insights into the mechanism underlying these diseases 
(Biedler et al. 1973). The following cell lines are of 
special value to the study of neuronal cells. 
1.3.1 PC-12  
Amongst all neuronal cell lines, the PC-12 cell line is 
one of the most studied to date (Green 1995). This 
line was cloned by Greene and Tischler (Greene & 
Tischler 1976) from a rat pheochromocytoma. In culture medium containing serum 
PC-12 cells undergo mitosis and show some properties of adrenal chromaffin cells. 
The cells are also able to synthesise acetylcholine and the catecholamines 
dopamine and norepinephrine, but not epinephrine (Greene 1978; Greene & 
Tischler 1976). When nerve growth factor (NGF) is added to culture medium, neurite 
outgrowth can be seen after about 7 days (Figure 6; Das et al. 2004).  
 
NGF is known to have a variety of effects on neurons, including increase in cell size, 
induction of certain enzymes involved in neurotransmitter synthesis and the 
stimulation of neurite outgrowth as well as increasing the survival of these neurones 
(Greene 1978). 
As PC-12 cells have been utilised in scientific research for many years, a number of 
different cell culture protocols have been developed. Most employ a culture 
medium of DMEM (Dulbecco’s Modified Eagle Medium) or RPMI 1640 (Roswell Park 
Figure 6: PC-12 cells day 1 and day 2 after seeding. 
PC-12 
Shape: round, elliptical, 
clumpy 
Size: 5-31 µm 
Cell cycle: 3-5 days 
Chapter 1 | Sandra Bednar 
 
p a g e  34 of 156 
 
Memorial Institute 1640) with glutamine, supplemented with heat-inactivated horse 
serum, foetal bovine serum and penicillin/streptomycin, at varying percentages. 
Cultures are maintained at 37°C with 5% (v/v) CO2, and for experimental purposes 
the cells are used at 70-80% confluency (Aykin-Burns et al. 2005; Das et al. 2004; Fujii 
et al. 1982; Green 1995; Robinson & McGee  Jr. 1985; Sadasivan et al. 2006). 
 
Figure 7: PC-12 cell differentiation observed following treatment with NGF 
after 0 (A) and 7 days (B) (Das et al. 2004). 
 
1.3.2 SH-SY5Y 
In the early 1970s, SK-N-SH cells were established 
from a bone marrow biopsy of a neuroblastoma 
patient (Biedler et al. 1973). The SH-SY5Y cell line is a 
thrice cloned subline of the neuronal phenotype (N 
type) of SK-N-SH (Ciccarone et al. 1989). Culture 
medium for SH-SY5Y is composed of DMEM or  MEM:F12 Ham 1:1 (Eagle’s Minimum 
Essential Medium : Ham’s F12 Medium) plus 10% (v/v) fetal bovine serum and 
penicillin/streptomycin. 
The SH-SY5Y cell line shows many characteristics of dopaminergic neurons and 
therefore is potentially a useful cell model for PD. Not only do SH-SY5Y cells possess 
the ability to synthesize dopamine and noradrenaline, but they also can be 
differentiated into a more distinct dopaminergic neuronal phenotype in the 
presence of agents such as retinoic acid (Cheung et al., 2009).   
Although SH-SY5Y is considered a good cell model for PD and is widely used, this 
cell line may not be a suitable model when the cells are in an undifferentiated state. 
Undifferentiated cells do not express high levels of dopaminergic synthetic 
SH-SY5Y 
Shape: round, elliptical 
Cell cycle: 7-8 days 
Number of generations 
after isolation: 20 
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enzymes, and display fewer dopamine receptors; also, they are less sensitive to 
neurotoxins and neuroprotective agents (Xie et al. 2010). 
 
Upon differentiation of SH-SY5Y cells, cell proliferation ceases and neurite outgrowth 
can be observed, with morphological parallels to living neurons in the human brain. 
Several protocols for differentiation exist, and  different agents induce alternative 
phenotypes which can therefore be used as different neuronal cell models 
(adrenergic/dopaminergic/cholinergic) (Xie et al. 2010).  
 
 
Figure 9: A: SH-SY5Y cells in regular culture medium B: SH-SY5Y 
cells differentiated with retinoic acid at day7 (Lopes et al. 2010). 
Figure 8: SH-SY5Y cells cultured at low and high density. 
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1.3.3  PRIMARY NEURONAL CELLS 
In contrast to the immortal cell lines mentioned above, primary neuronal cells 
(PNCs) do not divide in culture. They are plated directly after isolation from animal 
brain tissue (Gennaro Giordano and Lucio G Costa 2011).  These cells are also used 
to study basic characteristics of neurons and the potential neurotoxicity of 
chemicals. After plating, PCNs form synapses and become electrically active, 
demonstrating a neuronal phenotype, before they eventually die (Gennaro 
Giordano and Lucio G Costa 2011). 
The first primary neurons were cultured in vitro in the early 1900s, using ‘hanging 
drop’ method, which was simple to assemble and suitable for microscopic imaging, 
but problematic for cell and morphological identification (Millet & Gillette 2012). 
Many alternative methods have since been developed. 
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1.4 AUTOPHAGY 
As one of the more recent target fields identified for SFN, autophagy has also been 
associated with neurodegeneration and is therefore a pathway of great interest for 
this study. Autophagy is one of the main degradation mechanisms within the cell, 
which is most often triggered by starvation (Rubinsztein et al. 2007). Various forms of 
autophagy have been identified, which all share the common element of 
transporting cytoplasmic organelles into the lysosome (Mizushima 2007). The three 
major types of autophagy in eukaryotic cells are macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA), which differ in the 
mechanism by which cellular components are imported into the lysosome. Some 
proteins contain certain pentapeptide motifs recognised by a lysosomal receptor 
protein, which enables these proteins to pass the lysosomal membrane, however a 
chaperone (CMA) is needed to unfold the substrates (Rubinsztein et al. 2007; Jaeger 
& Wyss-Coray 2009). In macroautophagy, a double-membrane vesicle 
(phagophore) sequesters cytoplasm and/or organelles into a double-membrane 
limited organelle (autophagosome). The autophagosome then fuses with a 
vacuole/lysosome, in which the contents undergo degradation owing to the acidic 
environment within the lysosome (Figure 10) (Yang & Klionsky 2009). In 
microautophagy, the lysosome secludes cytoplasmic content without a pre-
lysosomal sequestration stage (Rubinsztein et al. 2007). As SFN has been linked to 
the activation of macroautophagy, it is the most relevant mechanism for this project 
and will now be referred to as autophagy. 
 
The induction of autophagy starts with the activation of the Atg1-ULK complex 
(Figure 11). The association of mTORC1 (TOR complex 1; TOR = target of rapamycin) 
Figure 10: Outline diagram of autophagy. 
This diagram shows the formation of the autophagosome in response to 
starvation, subsequent sequestration of damaged proteins and organelles, 
and fusion with the lysosome, which results in free amino acids. 
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with this complex and the activity of mTORC1 is controlled by cellular nutrient status. 
During starvation, the amount of free amino acids within the cytoplasm is 
insufficient, which triggers the dissociation of mTORC1 from the ULK1/2 complex, 
which in turn leads to partial dephosphorylation of Atg13 and ULK1/2 (Yang & 
Klionsky 2010). Nucleation begins with the recruitment of Atg proteins for formation 
of the phagophore. Atg14, a Beclin1-binding protein and a specific subunit of the 
PI3K III complex (class III phosphatidylinositol 3-kinase), mediates nucleation of the 
phagophore membrane. The protein Bcl-2 (B-cell lymphoma 2) prevents this step 
by binding to and inhibiting Beclin1, another component of the PI3K-complex 
together with the catalytic subunit Vps34 (vacuolar protein sorting 34) (Yang & 
Klionsky 2010). Vps34 generates phosphatidylinositol triphosphate (PI3P) necessary 
for autophagy by targeting PI3P binding proteins, and initiates activation of the first 
of two ubiquitin-like reactions (Gottlieb & Carreira 2010; Nixon 2013). First, the Atg12-
Atg5-Atg16 complex is formed and directed to the phagophore assembly site (PAS) 
for phagophore elongation (Nixon 2013). Atg7 (a ubiquitin-activating enzyme) and 
Atg10 (a ubiquitin-conjugating enzyme) mediate the covalent binding of Atg12 to 
Atg5, which then conjugates with Atg16 to form a tetrameric structure which 
assembles on the phagophore (Yang & Klionsky 2009; Gottlieb & Carreira 2010). The 
Atg12-Atg5-Atg16 complex induces a second ubiquitin-like reaction, which involves 
the removal of the terminal cysteine residue of LC3 (microtubule-associated protein 
1 light chain 3; homolog of yeast Atg8) by Atg4, a cysteine protease, to form LC3-I 
(Klionsky et al. 2011; Nixon 2013). Cytosolic LC3-I is then lipidated by Atg7 (a 
ubiquitin-activating enzyme) and conjugated to phosphatidylethanolamine (PE) by 
Atg3 (a ubiquitin-conjugating enzyme) to form LC3-II (Gottlieb & Carreira 2010).  
LC3-II is a useful marker of autophagosome formation. Although larger than the LC3-
I form, it migrates faster during electrophoresis and is identified at an apparently 
lower molecular weight (LC3-I at 18kDa and LC3-II at 16kDa) owing to its lipidated 
state (Cherra 3rd et al. 2010). Alternative methods to assess autophagy are 
described subsequently (see p.42). 
LC3-II is attached to both the interior and exterior of the phagophore, but once 
autophagosome formation is completed it is recycled from the outer membrane by 
the activity of Atg4, which separates LC3-II from PE (Yang & Klionsky 2009; He & 
Klionsky 2009). This is followed by fusion of the autophagosome with a lysosome to 
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form an autolysosome. The acidic environment of the lysosome facilitates the 
degradation of the inner autophagophore membrane, which is mediated by a 
number of lysosomal acid hydrolases (He & Klionsky 2009). Amino acids and other 
small molecules which result from the degradative process are transported into the 
cytosol through permeases, to be utilised in protein synthesis and maintenance of 
cellular function (Chen & Klionsky 2011). 
Vacuole membrane protein 1 (VMP1) also interacts with Beclin1 and is necessary 
for autophagy, as it localises to the plasma membrane or the endoplasmic 
reticulum (ER) (Klionsky et al. 2011). 
Induction of autophagy. Although the major physiological inducer of autophagy is 
nutrient depletion, it is also activated as a cellular response to various stress 
conditions including ER-stress, hypoxia, DNA damage and increased levels of ROS 
(Kroemer et al. 2010). Figure 12 displays most of the proautophagic pathways and 
their mechanisms of initiation. Sirtuin1, for example, is a deacetylase that senses 
environmental stress (Kroemer et al. 2010), while AMPK (5' adenosine 
monophosphate-activated protein kinase) is modulated by the energy status of the 
cell according to the AMP:ATP ratio (Efeyan et al. 2015).  
Selection of defective cargo. Autophagy has many physiological roles. It is 
responsible for the disposal of damaged organelles, the turnover of long-lived 
proteins and the clearance of proteins susceptible to aggregation. Although 
autophagy is generally considered a nonselective pathway for the degradation of 
cytoplasmic bulk organelles, some types of selective autophagy also exist (Yang & 
Klionsky 2009). The protein p62 directly binds poly- or mono-ubiquitin via its ubiquitin-
associated domain to LC3 and thus links ubiquitinated organelles to the autophagic 
pathway for degradation (He & Klionsky 2009; Klionsky et al. 2011). p62 is described 
in more detail on page 42. 
When autophagy is impaired or inactivated, this can result in cytoplasmic protein 
inclusions composed of misfolded proteins and conglomeration of deformed 
organelles, which may underlie the development of conditions such as diabetes, 
myopathy and neurodegeneration (Komatsu & Ichimura 2010).   
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Figure 11: Schematic representation of the major components in the mammalian 
autophagy pathway.   
Autophagy can be divided into induction, elongation and vacuole formation. The Atg 
proteins (shown in dark blue) can be grouped according to their different functions 
throughout the pathway. Atg1 (not shown) is important for the formation of the ULK1/2 
complex. The Atg12-Atg5-Atg16 complex is necessary for vesicle expansion, while LC3-
II (Atg8 in yeast) is involved in the completion of the autophagosome. (Arrows indicate 
activation, while blunted arrows show inhibition. Adapted from (Yang & Klionsky 2009; 
He & Klionsky 2009; Yang & Klionsky 2010; Gottlieb & Carreira 2010; Chen & Klionsky 
2011; Klionsky et al. 2011; Nixon 2013).     
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Figure 12: Selection of Autophagy Regulators  
These diagrams show both starvation induced and stress induced signalling cascades. Displayed 
are the sirtuin-1, AMPK and AKT/ERK pathways on the left and pathways triggered by ER-stress, 
hypoxia, ROS and p53 on the right. 
Sirtuin1, a deacetylase that senses environmental stress, (1) connects with tuberous sclerosis 
complex 2 (TSC-2) to further inhibit mTORC, (2) leads to deacetylation of Atg genes like Atg5, Atg7 
and LC3, and (3) can deacetylate FOXO3 to enhance the expression of proautophagic Bnip3.  
AMPK can be activated either by energy depletion (-> liver kinase B1(LKB1)) or through cytosolic 
Ca2+ (->calcium/calmodulin kinase kinase-β (CaMKKβ). When activated, it induces ULK1/2, 
inhibits mTORC, and can activate TSC-2 to in turn inhibit mTORC. 
The inhibition of TSC-2 can also be initiated by AKT and ERK1/2 in response to growth factors.  
ER-stress can lead to several unfolded protein response s(UPR) such as PERK (PKR-like elF2α kinase), 
ATF6 (activating transcription factor-6) and IRE1 (inositol requiring enzyme 1), of which IRE is the 
only negative regulator of autophagy. Hypoxia can induce PERK and DJ-1, which regulates 
autophagy by an unknown mechanism.  
Oxidative stress induces autophagy via ROS and p53. ROS can activate PERK, Atg4 and JNK1 (c-
Jun N-terminal kinase-1). P53 is activated by different types of stress, including ROS. p53 plays a 
dual role, as nuclear p53can activate autophagy via AMPK and JNK1, but also inhibit autophagy 
via its cytoplasmic functions. Arrows indicate activation while blunted arrows in red indicate 
inhibition. Adapted from (Kroemer et al. 2010). 
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Methods to measure autophagy. The basic approach to investigating autophagy is 
assessing the number of autophagosomes present within the cell. This can be 
achieved either by counting the punctae produced in a GFP-LC3 puncta formation 
assay by fluorescence microscopy, or by detection of the LC3-conversion through 
immunoblotting (Mizushima et al. 2010). LC3 in general is an important marker, as it 
is involved in autophagosome formation, and the change from LC3-I to LC3-II 
should correlate with the number of autophagosomes produced (Mizushima & 
Yoshimori 2007). However, autophagy is a dynamic process that can be influenced 
at many steps, and the amount of LC3-II alone cannot indicate if a compound has 
induced autophagy, or alternatively if the degradation pathway/fusion of the 
autophagosome with the lysosome is inhibited (Klionsky et al. 2008). Therefore, 
several authors have recommended determining the so called “autophagic flux” 
and thus including autolysosome formation to cover both  autophagosome 
synthesis as well as its degradation (Klionsky et al. 2008; Mizushima et al. 2010; 
Rubinsztein et al. 2009). By adding lysosomal inhibitors such as bafilomycin, which 
neutralises the lysosomal pH and therefore inhibits the degradation process; and 
comparing samples in the presence or absence of  a particular compound, the 
more dominant pathway (synthesis or degradation) can be assessed (Rubinsztein 
et al. 2009).  
Another option is to differentiate between autophagosome and autolysosome 
formation by using a tandem fluorescent-tagged LC3 plasmid (mRFP-GFP-LC3) 
which can be visualised by fluorescent microscopy. As GFP is degraded in the 
acidic environment of the lysosome, only a red signal is visible, whereas in the intact 
autophagosome  yellow fluorescence results from the combination of mRFP and 
GFP (Kimura et al. 2007). 
Another marker used to measure autophagy is p62, which is also called 
sequestosome 1(SQSTM1) in humans or ZIP in rats (Bjorkoy et al. 2009). It is a 
multifunctional protein containing several protein-protein interaction domains, 
suggesting that p62 is involved in the regulation of multiple signalling pathways 
(Salminen et al. 2012). p62 appears to selectively bind to toxic cellular waste and 
control its degradation or aggregation, by autophagy or proteasomes (Lamark et 
al. 2009; Salminen et al. 2012). Within the autophagic process, p62 is degraded 
(Figure 11), but also interacts with Nrf2 (Rusten & Stenmark 2010). As a marker for 
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autophagy, p62 levels would be expected to decrease over time when autophagy 
is induced.  
However, SFN can increase the levels of “free” Nrf2 by reacting with the thiol groups 
present in Keap1 and so disrupting the Nrf2-Keap1 complex, thus, especially after 
longer treatment times with SFN, p62 levels should be rising (Cheung & Kong 2009; 
Tufekci et al. 2011). Jain et al. (2010) reported a positive feedback loop between 
p62 and the Keap1-Nrf2 pathway, which in theory can be broken either by 
autophagy (degradation of p62) or the accumulation of small MAF proteins 
(repression of p62) (Figure 13). 
Autophagy and Neurodegenerative Diseases. A common factor in NDs is the 
presence of intracellular protein accumulations. As autophagy is an important 
pathway for degradation of such proteins, reduced activity of this process could 
contribute to the development of neurodegenerative diseases (Rubinsztein 2006; 
Rubinsztein et al. 2007; Sarkar 2011). A recent review has summarised the function 
of autophagy in development of PD, AD and HD, indicating different impairments 
within the autophagic pathway in each condition (Details see Table 1; Cheung & 
Ip 2011). Autophagy may therefore represent an interesting therapeutic target for 
these NDs, to reduce the levels of toxic protein aggregates and enhance the 
cellular response to stress (Nixon 2013). However, knowledge of  alterations in 
molecular mechanisms of autophagy in NDs is incomplete; and to date studies 
have reported  conflicting outcomes as to whether manipulation of autophagy  
can result in adequate neuronal survival (Cheung & Ip 2011; Jaeger & Wyss-Coray 
2009). 
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Figure 13: Modulation of the Nrf2 pathway and p62 by SFN. 
In basal conditions, two Keap1 molecules bind to Nrf2, resulting in polyubiquitinated of 
Nrf2 and degradation by the proteasome. SFN can bind to Keap1 by interacting with 
cysteine thiol groups to impair the ubiquitination of Nrf2. Nrf2 then translocates into the 
nucleus, where it binds to the antioxidative response elements (ARE) upstream of 
cytoprotective genes such as GST and HO-1, but also p62. SFN increases autophagy, 
which results in degradation of p62. Binding of p62 to Keap1 results in further activation of 
Nrf2 and therefore leads to a positive feedback loop. 
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Neurodegenerative 
disease 
Autophagy deregulation 
PD  Defective targeting of damaged mitochondria or mitophagy 
  Impaired lysosomal degradation 
AD  Generation of β-amyloid from autophagic vacuole 
  Impaired clearance of autophagic vacuole 
HD  Defective cargo recognition 
  Elevated autophagosome formation following mutant huntingtin expression 
ALS  Defective cargo recognition 
  Impaired autophagosome-lysosome-endosome fusion 
Table 1 Autophagic impairment in Parkinson‘s disease (PD), Alzheimer‘s disease 
(AD), Huntington‘s disease (HD) and amyotrophic lateral sclerosis (ALS).  
Mutation of Parkin and PINK1 are associated with targeting of damaged 
mitochondria to the mitophagy pathway in PD, but there is also increased 
autophagosome formation and possibly impaired lysosomal degradation. 
Pharmacological activation of autophagy can improve the clearance of α-
synuclein and is neuroprotective. AD is characterized by increased 
autophagosome formation together with elevated β-amyloid production from the 
autophagic vacuole, as well as impaired clearance of autophagic vacuoles. HD 
has been associated with defective cargo recognition and - when challenged 
with mutant huntingtin - elevated autophagosome formation, although the 
application of an autophagy inhibitor can also alleviate accumulation of mutant 
huntingtin and toxicity. mTOR is sequestered into huntingtin inclusions, which 
causes activation of autophagy. ALS has been associated with p62 mutations, 
resulting in impaired substrate recognition. Mutant ALS2-mediated Rab5 [which 
has been associated with the Beclin1/Vps34 complex (Ravikumar et al. 2008)] 
suppression can result in dysfunctional fusion of the autophagosome with the 
lysosome or endosome, thus decreasing the rate of lysosome protein degradation, 
increasing autophagosome accumulation and subsequent neurodegeneration 
(adapted from Jaeger & Wyss-Coray 2009; Cheung & Ip 2011; Nixon 2013) 
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1.5 PROJECT AIMS 
 
 To verify previously reported bioactivity of SFN in neuronal cell lines 
Based on the reviewed literature, the actions of SFN on neuronal cells have 
not been well researched. Some previously described bioactivities of SFN in 
other cell lines have been linked to potentially beneficial effects in NDs. The 
effects of SFN will be determined by measuring effects on the cell cycle, 
apoptosis, autophagy and the expression of phase II enzymes, as well as the 
capacity of SFN to protect neuronal cells from toxin-induced cell death. PC-
12 and SH-SY5Y cell lines will be used to simulate neuronal cells. 
 
 To investigate ER-stress regulators as potential downstream targets of SFN 
Targets tested will include DJ-1, a protein associated with PD, as well as 
CHOP, a marker for ER-stress, while ER-stress will be induced by tunicamycin.  
The role of DJ-1 in reducing ER-stress will be further researched by silencing 
DJ-1 using siRNA. 
 
 To examine the importance of autophagy in SFN-mediated cell survival 
This study will examine whether primary neuronal cells generated from 
Atg16L1 deficient mice show a reduced capacity to recover from H2O2-
induced cell death in the presence of SFN. The occurrence of autophagy 
will be compared in SFN-treated Atg16L1 knock out (KO) and wild type (WT) 
cells. Furthermore, the effect of impairment of autophagy on the protective 
effects of SFN will be determined. 
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2 MATERIALS AND METHODS 
2.1 CELL CULTURE 
2.1.1 PC-12 CELLS 
2.1.1.1  MEDIA USED FOR ROUTINE CULTURE OF CELLS 
The PC-12 cell line was maintained in Kaighn’s Modification of Ham’s F-12 Medium 
(F-12K; LGC Standards; contains 1.26 g/l D-glucose), supplemented with 2.5% (v/v) 
Fetal Bovine Serum (FBS; Invitrogen), 15% (v/v) Horse Serum (HS; LGC Standards) and 
1% (v/v) Penicillin-Streptomycin (PEN/STREP 5000U/ml; Gibco). This media 
composition will be referred to as complete PC-12 media from this point forward. 
The cells were usually grown in 75cm2 flasks with 12ml medium at seeding density of 
1 – 1.5x106 cells. 
2.1.1.2  SUBCULTURE OF CELLS 
All flasks were labelled with name, date of seeding, cell line and passage number. 
Prior to subculture, the cells were checked for the ideal cell confluency (~70-80% 
growth density) and any signs of contamination. The cells were detached with TE 
(0.25% (w/v) trypsin/1mM EDTA; Gibco) and cell numbers were calculated using a 
haemocytometer. 
At a seeding density of 1 – 1.5 x 106 cells were split every 3-4 days.  
2.1.1.3 CRYOPRESERVATION AND CONTROLLED FREEZING OF CELLS 
An estimated number of cryotubes were labelled with the user name, cell line, 
passage number, date and amount of cells (usually 1,5 x 106).  The cells were then 
harvested as described above (2.1.2). The cells were spun down (5mins at 200G) 
and freezing medium (complete media + 5% (v/v) DMSO) was added. The 
resuspended cells were transferred into cryotubes in 1ml aliquots which were then 
put into a freezing container (Nalgene®Mr. Frosty, Sigma-Aldrich) at -80°C for one 
day and then kept in liquid nitrogen for long term storage. 
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2.1.1.4  DIFFERENTIATION OF PC-12 CELLS 
Plates were coated with collagen at a concentration of 0,4mg/ml and placed in 
the incubator at 39°C for 30mins. PC-12 cells were then seeded into 12-well plates 
at a density of 10.000 or 20.000 cells/well using DMEM-Hi media (Gibco) 
supplemented with 15% (v/v) Foetal Bovine Serum (FBS; Invitrogen) + 1% (v/v) 
Penicillin-Streptomycin (PEN/STREP 5000U/ml; Gibco). After 2-3 days only ~75% of the 
media was changed to not stress the cells. 2 days later, at ~50% confluency, the 
media was replaced with NGF-containing media [DMEM-Hi + 15% (v/v) FBS + 1% 
(v/v) P/S + 50ng/ml NGF]. Going forward, fresh media was added every 2-3 days 
until differentiation was visibly confirmed (usually within 5-7 days after start of NGF 
treatment).  
2.1.2 SH-SY5Y CELLS 
2.1.2.1 MEDIA USED FOR ROUTINE CULTURE OF CELLS 
The SH-SY5Y cell line (ATCC-CRL-2266) was kept in a 1:1 mixture of Eagle’s Minimum 
Essential Medium (MEM; LGC Standards; contains 1 g/l D-glucose) and Ham’s F12 
Medium (F12-HAM; Sigma Aldrich; contains 1.802 g/l D-glucose) supplemented with 
10% (v/v) FBS and 1% (v/v) PEN/STREP. The volume of medium used in routine cell 
culture was 12ml in a T75 flask. The cells were usually grown in 75cm2 flasks with 12ml 
medium at seeding density of 2x106/flask. 
1.1.1.1 SUBCULTURE OF CELLS 
The cells were detached with TE (0.25% trypsin/1mM EDTA; Gibco) and counted with 
a haemocytometer. SH-SY5Y cells also include floating cells, which were spun down 
at 200G for 5mins, resuspended in fresh media and then added to the new flask. 
When 2 x 106 cells were seeded, they could be harvested after 8-10 days. 
1.1.1.2 CRYOPRESERVATION AND CONTROLLED FREEZING OF CELLS 
See 2.1.1.3 
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2.2 MTT ASSAY 
3-(4,5-Dimethyilthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Aldrich) is 
a yellow coloured tetrazol, which is reduced into a purple formazan in living cells. 
5mg/ml MTT was dissolved in sterile PBS. The MTT reagent was kept at 4°C, protected 
from light, and used within 3 months.  
Cells were seeded in 96 well plates 100µl/well at 1 x 106/10ml (SH-SY5Y: 1.5 x 
106/10ml). The first column was used as blank control samples. The following day, 
the cells were checked for complete attachment. The media was changed twice 
over the next two days, the second time replaced by different treatment solutions 
for each column. The plate was kept in the incubator for 24h. Prior to the MTT 
treatment, 800µl of MTT solution was added to 8ml pre-warmed media. The media 
was removed from the plate and replaced by the MTT/media mix. After a 1h 
incubation at 37°C, MTT/media was removed from the wells. 100µl DMSO, serving 
as a solvent of the purple formazan precipitate, was added to each well and mixed 
thoroughly by pipetting. The plate was then slightly tapped to ensure even and 
bubble-free distribution before reading it at 550nm test wavelength and 630nm 
reference wavelength.  
 
 
Mean Absorbance of Sample 
Mean Absorbance of Control 
x 100 % Viability =  
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2.3 WESTERN BLOT 
2.3.1 PROTEIN EXTRACTION 
To minimize protein degradation, samples and lysis buffer were kept on ice as much 
as possible. Cells were lysed in NP40 lysis buffer {Tris-EDTA pH8 (2mM), NaCl (150mM), 
Glycerol (10% (v/v)) and Nonidet P40 (1% (v/v))} plus Complete Protease Inhibitor 
mini tablet [EDTA-free], incubated on ice for 30min, dislocated from the plates using 
cell scrapers, and finally centrifuged at 13000rcf at 4°C for 15min. The supernatant 
was collected into cold 0.5ml Eppendorf tubes and stored at -20°C. 
Nuclear protein extraction. Cells were washed with ice-cold PBS (incl. phosphatase 
inhibitors) before they were evenly covered with 1x Hypotonic buffer and 
incubated on ice for 30min while kept in motion. After dislocating the cells from the 
plates using cell scrapers and collecting them in individual Eppendorf tubes, 
detergent was added to each vial. These tubes were vortexed for 10sec at highest 
setting and centrifuged for 80sec at 14.000g at 4°C. The supernatant (cytoplasmic 
fraction) was transferred into a pre-chilled Eppendorf tube and stored at -80°C until 
used. The nuclear pellet was resuspended in complete lysis buffer and again 
vortexed for 10 sec at highest setting. After incubation for 30min at 4°C in motion, 
another 30sec vortex and centrifugation for 10min at 14.000g at 4°C, the 
supernatant (nuclear fraction) was transferred into a pre-chilled Eppendorf tube 
and stored at -80°C until used (see appendix Table 8, p.135, for details on solution 
compositions). 
Total protein was collected unless otherwise noted. 
2.3.2 PROTEIN QUANTIFICATION (BRADFORD ASSAY) 
The Bradford assay is a colorimetric protein assay based on the binding of the dye 
Coomassie Blue G-250 to protein. Bovine serum albumin (BSA; Thermo Scientific) was 
used to create a standard dilution series, for which samples were prepared within 
the range of 0.25 – 2mg/ml. All standards and samples were prepared in duplicates. 
The samples were transferred into cuvettes and read in a spectrophotometer at 
595nm. The absorbance was read from the standard curve to convert the results 
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into protein concentrations in mg/ml. Usually, 20ng of protein was used for 
separation and further investigation. 
2.3.3  WESTERN BLOT 
2.3.3.1 GEL ELECTROPHORESIS – SDS PAGE 
Samples were mixed with 4x loading buffer (NuPage LDS sample buffer (4x); 
Invitrogen) and DTT (Sigma Aldrich) to obtain final concentrations of 70% (v/v) 
sample, 25% (v/v) loading buffer and 5% (v/v) DTT (1M).  10µl/20µl/30µl samples were 
prepared, from which a calculated volume containing 20ng protein was loaded on 
a gel. After mixing all contents with vortex, the samples were put in a heating block 
set to 98°C for 5min to denature the protein.   
The gels contained either 10% (v/v) or 12.5% (v/v) resolving gel and were prepared 
not longer than 3 days before use, wrapped in cellophane and kept in the fridge. 
Depending on the amount of samples, either 10- or 15-well combs were used. The 
gels were placed in a MINI Protean Tetra Tank (Bio Rad) for four gels or a MINI 
Protean Tank (Bio Rad) for one or two gels, according to manufacturer’s instruction. 
The electrophoresis was run at 200V for 30-35 minutes (Tetra Tank) or at 25mA for 40-
60 minutes (Regular Tank). The run was stopped when the blue dye from the sample 
loading buffer has come close to the bottom of the gel. 
2.3.3.2 SEMI-DRY GEL TO MEMBRANE TRANSFER 
To transfer the proteins from the gel onto the membrane, the Trans-Blot SD Semi-Dry 
Transfer Cell (Bio Rad) was used. A transfer buffer was made up of 10% (v/v) transfer 
buffer (10x; Bio Rad), 20% (v/v) methanol (Sigma Aldrich) and 70% (v/v) water (MQ). 
Pre-cut filter paper was soaked in this transfer buffer. PVDF-membranes were 
incubated in methanol for 10sec before they also were left in transfer buffer for 
about 10mins. The filter paper, the membrane, the gel and again some filter paper 
were laid onto the plate. The filter paper is pressed a little with the fingers to remove 
most of the liquid before building this sandwich. After each layer is applied, a small 
glass pipette is rolled gently over it to remove unwanted bubbles. One gel was run 
at 15V, two at 25V for 50mins. 
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2.3.3.3 MEMBRANE BLOCKING AND STAINING 
After the transfer, the membrane was washed in PBST 0.1% (PBS pH 7.4 containing 
0.1% (v/v) Tween 20). Then the membrane was put into a box with 25ml of blocking 
buffer (Fisher Scientific) to block for 1-2 hours. The antibodies were prepared in a 1:1 
solution of blocking buffer and PBST 0.5% (PBS pH 7.4 containing 0.5% (v/v) Tween 
20) accorded to recommended dilutions (see Table 2).  
 
To the secondary antibody, SDS was added to reach a final concentration of 0.01% 
(v/v) to reduce the background of 
the red IR signal (680nm), as recommended by the supplier. The membrane then 
was incubated with the primary antibody with gentle movement over night at 4°C. 
After 15-18 hours, the membrane was washed 4 times with PBST, before the 
secondary antibody was applied and left for 1 hour. Again, the membrane was 
washed 4 times with PBST and once with PBS prior to finally keeping it in PBS at 4°C 
until imaging by the Odyssey® Imaging System. For long term storage, the 
membrane was dried out on tissue for 1-2 hours, then on a fresh tissue for another 1-
Type of AB Antigen Host Dilution Size / IR Dye Supplier Cat.no. 
Primary β-actin goat 1:10000 42kDa Santa Cruz 
Biotechnology 
sc-1615 
Primary LC3 rabbit 1:2000-
1:5000 
18kDa + 
16kDa 
Sigma L7543 
Primary p62 guinea 
pig 
1:2500-
1:5000 
62kDa Progen GP62-C 
Primary Nrf2 (C-20) 
(cytosol) 
rabbit 1:500 57/100kDa Santa Cruz 
Biotechnology 
sc-722 
Primary Nrf2 (H-300) 
(nuclear) 
rabbit 1:500 57kDa Santa Cruz 
Biotechnology 
sc-13032 
Primary α-synuclein rabbit 1:2000 14-19kDa Millipore AB5038 
Primary SAM 68  
(C-20) 
rabbit 1:10000 68kDa Santa Cruz 
Biotechnology 
sc-333 
Primary TR-1 rabbit 1:2000 55kDa Abcam AB16840 
Primary HO-1 mouse 1:2000 30/60kDa Abcam Ab13248 
Primary DJ-1 rabbit 1:1000 23kDa Santa Cruz 
Biotechnology 
sc-32874 
Primary CHOP 
(L63F7) 
mouse 1:1000 27kDa Cell Signalling 2895 
Secondary goat donkey 1:10000 -/680 Li-Cor 926-68024 
Secondary rabbit donkey 1:10000 -/800 Li-Cor 926-32213 
Secondary guinea pig donkey 1:10000 -/800 Li-Cor 926-32411 
Secondary mouse donkey 1:10000 -/800 Li-Cor 926-32212 
Table 2: Antibodies used in western blotting 
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2 hours before put on labelled whatman paper and wrapped in cellophane. The 
membrane must be protected from light. 
2.3.3.4 IMAGING WITH ODYSSEY 
The membranes were imaged using the Odyssey® Infrared Imaging System and 
analysed using the Odyssey software. The intensity of each channel – 700 for the 
red and 800 for the green signal – was adjusted to receive the best image results. 
The intensity measured for each band was aimed to be at least 10, but not higher 
than 200. The box drawing feature in the software enables to quantify the value 
selected in this specific area. Quantifying the bands makes calculations possible, 
such as normalisation, simply by dividing the value of the protein of interest by the 
value of the loading control. 
Chapter 2 | Sandra Bednar 
 
p a g e  54 of 156 
 
2.4 RNA/DNA EXPERIMENTS 
2.4.1 RNA EXTRACTION 
RNA extraction was carried out using the SIGMA RNA-extraction kit GenElute 
(Sigma-Aldrich) following the provided instructions. After lysing the cells, they were 
run through a filtration column for 2mins. The column binds the RNA, which is washed 
and 3 times prior to elution of pure total RNA. 
2.4.2 RT-PCR 
The RNA was transcribed into cDNA by using the SuperScript II kit (Invitrogen) 
following the provided instructions. In addition to the kit, Random primers, RNasin 
Plus (both Promega) and dNTP Mix (10mM; Invitrogen) were acquired. 1µg RNA was 
used in a 12µl reaction volume. After the SuperScript II RT is added, the mix is 
incubated at 25°C for 10min and at 42°C for 50min, before inactivating the reaction 
at 70°C for 15min.  
2.4.3 PCR 
The following reaction mix was assembled (Primers used can be seen in Table 3): 
Component Volume (µl) 
cDNA from RT-PCR 
(~83ng/µl) 
4 
5x GoTaq Flexi Buffer 10 
MgCl2 (25mM) 8 
dNTPs (10mM) 1 
Fwd primer (10µM) 2 
Rev primer (10µM) 2 
dd H2O 22,5 
Go Taq (5u/µl) 0,5 
Final volume 50 
 
 Fwd primer 
Temp. 
(C°) 
Rev primer 
Temp. 
(C°) 
CHOP CCTTGGAGACGGTGTCCAGC 69.4 CGCAGGGTCAAGAGTAGTGAAGG 68 
Actin GAGGCCCCCCTGAACCCTAAG 70.7 GAACCGCTCGTTGCCAATAG 66.7 
Table 3: CHOP and actin composition forward and reverse primer and annealing 
temperature. 
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2.4.4 TAQMAN REAL-TIME PCR 
mRNA levels were quantified by real-time RT-PCR (TaqMan®) using the AB 7500 PCR 
system. Probes and Primers were obtained by Applied Biosystems, as can be seen 
in Table 4. The experiments were carried out in a 96-well plate in a total volume of 
25µl per well. The samples were set up in 3 technical replicates. A standard curve 
containing 2 technical replicates was also present on each plate. “No template 
controls” (no cDNA, just water) were added to each plate. Data were normalised 
against the housekeeping gene 18S ribosomal RNA.  
 
Gene name  
Reporter / Quencher 
Primers and Probes Supplier 
G
O
I 
GST - rat  
Glutathion-S-transferase 
FAM/TaqMan MGB 
perfect probe 
Applied Biosystems 
TaqMan Gene 
Expression Assay 
TR-1 - rat 
Thioredoxin reductase 1 
FAM/TaqMan MGB 
perfect probe 
Applied Biosystems 
TaqMan Gene 
Expression Assay 
GST-α - human 
Glutathione-S-transferase 
FAM/TAMRA 
Forward: 5’ –CAGCAAGTGCCAATGGTTGA- 3’ 
Reverse: 5’ –TATTTGCTGGCAATGTAGTTGAGAA- 3’ 
Probe: 5’ –TGGTCTGCACCAGCTTCATCCCATC- 3’ 
Applied Biosystems 
TaqMan One-Step RT-
PCR master mix 
reagents kit 
TR1 - human 
Thioredoxin reductase 1 
FAM/TAMRA 
Forward: 5’-CCACTGGTGAAAGACCACGTT -3’ 
Reverse: 5’ –AGGAGAAAAGATCATCACTGCTGAT- 3’ 
Probe: 5’ –CAGTATTCTTTGTCACCAGGGATGCCCA -
3’ 
Applied Biosystems 
TaqMan One-Step RT-
PCR master mix 
reagents kit 
APP – rat 
 
FAM/TaqMan MGB 
perfect probe 
Applied Biosystems 
TaqMan Gene 
Expression Assay 
SYN – rat 
FAM/TaqMan MGB 
perfect probe 
Applied Biosystems 
TaqMan Gene 
Expression Assay 
H
G
 
18S ribosomal RNA 
FAM/TAMRA 
Forward: 5’–GGCTCATTAAATCAGTTATGGTTCCT-3’ 
Reverse: 5’-
GTATTAGCTCTAGAATTACCACAGTTATCCA-3’ 
Probe: 5’TGGTCGCTCGCTCCTCTCCCAC-3’ 
Applied Biosystems 
Table 4: Probes and primers used for qPCR 
 
2.4.5 TRANSFECTION WITH PLASMIDS 
Cells were seeded on cover slips in 24-well plates (30.000 cells in 500µl/well). The 
transfection reagent Xtreme Gene HP (Roche) was used for transient transfection 
on PC-12 cells according to the manufacturer’s instructions. For this project, the 
following plasmids were used, which were a kind gift from Dr. R. Roberts, Babraham 
Institute, Cambridge: 
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 mRFP-LC3 
 Atg16L1-GFP 
 p62-tomatored 
 mRFP/GFP-LC3  
PC-12 cells were seeded at a density of 30.000/well. A 1:3 mixture of 1µg plasmid 
DNA and X-tremeGENE HP DNA Transfection Reagent was prepared in serum-free 
media and added drop-wise to the wells after a 15-30min incubation period at 
room temperature to allow complex formation. After 48h, cells were treated with 
DMSO (0.025%), SFN (2.5, 5 and 10µM) or HBSS for 4h, then the treatment medium 
was removed. To fix the cells, they were covered with 200µl ice cold pure 
MeOH/well and left for 5mins. Then cells were washed with PBS, before 200µl of DAPI 
(1:2000; Sigma) were added for 2mins. After this step, cells need to be protected 
from light. After removal of the DAPI solution, the cells were left in PBS. Cover slips 
were carefully removed from each well and washed first in PBS, then in water, 
before placed topside down onto a drop of Hydramount (national diagnostics) on 
labelled glass slides. The slides were left for 15mins to harden, after which they were 
put into a sample box and kept in the fridge until imaging. They were visualised 
under the ZEISS Axioplan 2 imaging microscope and analysed using the Axio Vision 
Release 4.8 software. All results were magnified to 100x objective. 
2.4.6 TRANSFECTION OF PC-12 CELLS WITH SIRNA 
siRNA experiments were carried out according to recommendations from QIAGEN 
using their HiPerfection Transfection Reagent Kit.  
PC-12 cells were seeded at a density of 1x106/96well plate. The next day they were 
treated with the siRNA-HiPerfect mix as recommended (see Table 5). Another 24h 
later treatment with SFN was initiated. One day later the plates were either 
measured using MTT or exposed to H2O2 for another 24h, to be then analysed 
according to the experiment layout.  
The same procedure was followed for 6 well plate experiments at a seeding density 
of 1x106/plate (~80 000/well). 
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 96 well plates 
(amounts/well) 
6 well plates 
(amounts/well) 
Volume of HiPerFect Reagent (µl) 0.75 12 
Total volume of medium on cells (µl) 120 2300 
Final siRNA conc. 5nM 10nM 10nM 20nM 
siRNA of a 2µM stock solution (µl) 0.375 0.75 12 24 
Table 5: siRNA-HiPerfect mix components 
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2.5 FLOW CYTOMETRY 
2.5.1 CELL CYCLE ASSAY 
Cells were seeded in a 6 well plate (PC-12: 200 000; SH-SY5Y: 300 000 – 350 000/well). 
At 70-80% confluency, the wells were treated with different concentrations of SFN 
(2.5-20µM) for 24h. Then the media was collected in allocated tubes. The adhered 
cells were washed with PBS before detaching them from the plate with trypsin and 
adding them to the corresponding vial. The tubes were spun down at 270G for 5 
minutes. The pellets were resuspended in PBS and spun down again. This time, ice-
cold 70% (v/v) ethanol was added while vortexing the tube. Then the tubes were 
kept at -20°C. 
Next, the tubes were spun down at 500G for 5mins. The ethanol was removed and 
the cells were washed with PBS. A mixture of PBS, RNase-A (0.5mg/ml) and Triton-
X100 (0.3% v/v) was prepared, of which 25µl were added to each tube, after which 
the cells were resuspended in 50µl PBS. The samples were incubated at 37°C for 
30mins.  
After the incubation, 3µl propidium iodide (1mg/ml; Sigma-Aldrich) was added to 
each sample, which were then run on the BD Biosciences Accuri C6 flow cytometer. 
After gating the cells on a forward and side scatter plot excluding most likely debris 
(gate P1), forward scatter height and area data were used to gate for singlet cells. 
These were plotted on a histogram with FL2-A as filter setting for the x-axis. A 
minimum of 5000 events in gate P1 was collected. A method optimisation table can 
be found in the Appendix 1 (Table 3). Data was further analysed using the FlowJo 
Software. 
2.5.2 ANNEXINV/PI APOPTOSIS ASSAY 
The cells were seeded in and collected from 6-well plates as mentioned above 
(2.5.1), but instead of fixing the cells with ethanol, they were resuspended in 500µl 
binding buffer (1x!) provided with the AnnexinV-FITC Apoptosis Detection Kit 
(eBioscience). 100µl of this cell suspension was transferred into a new labelled tube. 
Next, 2µl AnnexinV-FITC (included in the kit, concentration information not 
provided) and 10µl PI (20µg/ml; included in the kit) were added. After incubation 
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at room temperature under light protection, the samples were run on the BD 
Biosciences Accuri C6 flow cytometer. 
The gated cells (P1) where then filtered by FL1-A on the X-axis and FL3-A on the Y-
axis on a new scatter plot. This could then be divided into 4 squares which show the 
different stages between healthy (AnnexinV-/PI-), apoptotic (AV+/PI-) and necrotic 
(AV+/PI+) cells. A minimum of 10000 events in gate P1 was achieved unless otherwise 
noted. Data was further analysed using the Kaluza Software. 
In cytoprotection assays cells were treated with SFN at an earlier stage (at ~60-70% 
confluency) to avoid overgrowth of cells at the end of the experiment, when cells 
were treated with H2O2 or 6-OHDA for 24h after SFN-pre-treatment (see method 
optimisation in appendix, Figure 48, p.136). 
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2.6 MOUSE WORK 
2.6.1 ANIMAL MAINTENANCE 
The mice used for the experiments mentioned were a kind donation of Prof. Uli 
Mayer’s lab at UEA. All mice were handled in accordance with Home Office 
regulations. They were kept in specific pathogen free conditions in individually-
ventilated cages and were routinely screened for common mouse pathogens. For 
generating primary neuronal cells, pregnant female mice were killed by schedule 
1 method 14-16 days into the pregnancy. 
2.6.2 RETRIEVING EMBRYONIC BRAINS 
The sacrificed pregnant mouse was dissected to extract the vitelline bag, which 
was then put into a Ca+2- and Mg+2-free PBS solution containing 33mM glucose (PBS-
glucose) and kept at 4°C. The dead embryos were removed and placed into 
individual wells of 6 well plates containing PBS-glucose. After decapitation of the 
embryos, the heads were placed into fresh individual wells filled with PBS-glucose. 
Under a microscope an incision at the back and either side of the head was made 
and with gentle pressure on top of the head the brain was released into the solution 
and immediately removed with a small sieve and placed into a labelled 1.5ml 
Eppendorf tube filled with PBS-glucose. 
2.6.3 GROWING PRIMARY NEURONAL CELLS 
Fire-polished Pasteur pipettes were rinsed with heat inactivated FBS before gently 
dissociating the cells of each Eppendorf tube. After 5-10 minutes, the non 
dissociated elements formed a pellet. The supernatant was pipetted into a fresh 
Eppendorf tube and centrifuged at ~200g for 5mins at room temperature. After the 
supernatant was removed, the cells were mixed with DMEM/F12 +10% (v/v) mixed 
hormones (see Table 6) in an amount based on number of wells to be plated, and 
seeded into poly- D-lysine pre-coated (incl. coverslips; for immunohistochemistry) or 
poly-ornithine pre-coated plates (for AV/PI experiments) [Coating Procedure see 
Appendix 8.4.3]. 
After 2 days, first morphological signs of differentiation could be observed. After 4 
days, the media was changed. After a week, treatment with SFN was started. For 
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AV/PI experiments, this was followed by a 4h exposure to H2O2 in Hepes buffered 
media (HBM) and further 20h of media + 10% (v/v) mixed hormones. 
Table 6: List of components of mixed hormones solution. 
This mixture is added to DMEM/F12 1:1 (Gibco, 11320-740, (1x), liquid – with L-
glutamine, without HEPES) as medium 
 MEDIUM FINAL CONCENTRATION SUPPLIER + CAT.NO. 
TRANSFERIN 100µg/ml Sigma T-2036 
INSULIN 25µg/ml Sigma I-1882 
PUTRESCINE 60µM Sigma P-7505 
SODIUM SELENATE 30nM Sigma S-9133 
PROGESTERONE 20nM Sigma P-6149 
2.6.4 MOUSE GENOTYPING 
The tail of each embryo used mentioned above was kept at 4°C until genotyped 
using PCR. About 150µl of proteinase K lysis buffer was added to each tail biopsy 
and left over night in a rotating incubator at 55°C. The lysate was then diluted 10 
times using distilled water, of which 3µl was used in a PCR reaction. 
The following reaction mix was assembled: 
Component Volume (µl) 
DNA (1:10 dilution from lysis) 3 
10x buffer (containing MgCl2) 5 
dNTPs (25µM) 0.5 
Primer mix (20pmol/µl) 1 
Taq 2 
dd H20 X  
Final volume 50 
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For amplification of genomic DNA, a touchdown PCR method was applied: 
95°C – 10 min 
95°C – 45 sec  
65°C – 1min/ minus one degree each cycle 
 10 cycles 
72°C – 1 min  
95°C – 45 sec  
55°C – 1min 
 25-30 cycles 
72°C – 1 min  
72°C – 10 min 
4°C   –  on hold 
The PCR products were then run on a 1% agarose gel. 
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2.7 IMAGING 
2.7.1 IMMUNOFLUORESCENCE 
Cells were fixed by adding ice cold pure methanol for 5 minutes. After several 
washes with PBS, the slides were blocked with 2% (w/v) BSA in PBS at room 
temperature for 1h. This solution was then replaced by the primary antibody (see 
Table 7) at room temperature for 1h. After 3 washes with 2% (w/v) BSA in PBS the 
second antibody was left on for 40 minutes at room temperature. Once the 
antibody and BSA was washed off, a solution of DAPI 1:5000 was added to the wells 
for 5-10 minutes. Following more washes, the slides were finally mounted using 
Hydromount (national diagnostics) and dried under protection of light. The slides 
were imaged under the microscope. 
2.7.2 MICROSCOPY 
Fixed cell images were captured at x63 magnification on a Zeiss Axioplan 2 
microscope, unless specified otherwise. Images were analysed with the Axioplan 
software version 4.7.1. IMARIS was used to calculate autophagy punctae. 
 
 
TYPE OF AB ANTIGEN HOST DILUTION SUPPLIER CAT.NO. 
PRIMARY LC3 rabbit 1:1000 Sigma L7543 
PRIMARY p62 guinea pig 1:1000 Progen GP62-C 
SECONDARY rabbit donkey 
594 
1:500 Invitrogen * 
SECONDARY guinea pig goat 488 1:500 Invitrogen * 
Table 7: List of antibodies used for immunofluorescence 
* These secondary antibodies were a kind gift from Matt Jefferson, Wileman lab, 
University of East Anglia. 
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2.8 STATISTICS 
For all results with 2 or more biological replicates, standard deviation and, if 
appropriate, Student’s t-test were calculated and, if statistically significant, were 
labelled with the P-value. Whenever more than pairwise comparisons were 
investigated within a data set, ANOVA was used to test for significance and post-
hoc t-tests were adjusted according to Bonferroni. 
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3 BIOACTIVITIES OF 
SULFORAPHANE ON PC-12 AND 
SH-SY5Y CELLS  
3.1 BACKGROUND & AIMS 
Before this study was initiated, no publications reported the actions of SFN on PC-12 
cells. However, Shibata et al. (2008) investigated cruciferous vegetable extracts on 
PC-12 cells on the search for the most potent natural enhancer of NGF-dependent 
neuritogenesis. Japanese horseradish (Wasabia jabonica) with its major ITC 6-
methylsulfinylhexyl isothiocyanate (6-HITC) was identified as the richest source of 
neurotrophic inducers within the Brassicaceae, and was further investigated on 
neurite outgrowth and the involvement of NGF. It was shown that 6-HITC could 
enhance the NGF-induced neurite outgrowth. 
Shavali & Sens (2008) demonstrated that SFN could protect SH-SY5Y cells from 
cytotoxicity caused synergistically by arsenite and dopamine. Concentrations 
between 0.1 and 2.5µM showed significant recovery of cell survival in a dose 
dependent manner, while the cell viability was reduced in 5µM SFN samples. In a 
different study, SFN could protect SH-SY5Y cells against H2O2 or 6-OHDA-induced 
cell death (Tarozzi et al. 2009). They also demonstrated significant increases in total 
GSH level, NAD(P)H quinone oxidoreductase-1, GSH-transferase and –reductase. 
The SFN concentrations used were between 1.25 and 2.5µM for 12 or 24h, followed 
by a 24h exposure to 300µM H2O2 or 100µM 6-OHDA. 
SFN has been introduced in depth in chapter 1 (page 15).  The aim of this chapter 
is to validate previous findings, therefore cell cycle, apoptosis, Nrf2 and Nrf2/ARE-
driven genes as well as autophagy will be measured. To investigate SFN in PC-12 
cells, basic assessments will be made to optimise concentrations of SFN and time 
lines for further experiments including toxins. 
Initiation of autophagy by autophagy. The first report of SFN inducing autophagy by 
measuring autophagy endpoints like autophagosome formation also looked into 
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the mechanism of action involved. 3-methyladenine (3-MA, a class III PI3K blocker) 
was effective to inhibit SFN-induced autophagy, so PI3K III could also be a target of 
SFN (Herman-Antosiewicz et al. 2006). SFN has previously been reported to reduce 
Bcl-2, an inhibitor of Beclin-1 and thus autophagy (Singh et al. 2005). The production 
of mitochondria-derived ROS by SFN has also been found to be a trigger for 
autophagy induction (Xiao et al. 2009). A more recent study in SH-SY5Y cells and 
cortical neurons however has suggested that the ROS further activates ERK, which 
in turn induces autophagy (Jo et al. 2014). Interestingly, the initial investigation of 
SFN and autophagy has argued against an involvement of ERK in sulforaphane-
induced autophagy. They reported an ERK activation by SFN, but since an inhibitor 
of ERK applied simultaneously failed to reduce LC3 production, it was concluded 
that ERK may not be involved in the mechanism of SFN on autophagy (Herman-
Antosiewicz et al. 2006). It is possible that SFN has several targets to initiate 
autophagy, or that it works differently in separate experiment models. The 
mechanism of autophagy initiation by SFN will not be investigated in this study. 
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3.2 RESULTS 
3.2.1  CELL VIABILITY OF SFN IN PC-12 CELLS 
To determine a dose range of SFN which keeps cells intact, cell viability was 
assessed using the MTT assay. To estimate the IC50 value, the results were analysed 
using the GraphPad Prism software. In 80% confluent PC-12 cells, 50% of cell survival 
can be expected at approximately 36.9µM SFN in 24h-treatments (=IC50) (Figure 14). 
 
Figure 14: Cell viability of PC-12 cells following exposure to SFN for 24h. 
PC-12 cells were treated with DMSO (0.05%) or different 
concentrations of SFN (10-40µM) for 24h. Cell viability was assessed by 
MTT and measured on a plate reader using 550nm as test wavelength 
and 630nm as reference wavelength. Each bar represents the 
average of six biological replicates (± standard deviation; *P<0.05 
compared to control). 
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3.2.2  EFFECT OF SULFORAPHANE ON CELL CYCLE ARREST IN PC-12 AND SH-SY5Y 
CELLS 
SFN on cell cycle in PC-12 cells. The results shown in Figure 15 indicate that SFN 
leads to S phase arrest in PC-12 cells. Untreated controls were primarily in the G1 
phase (51.83%) with smaller percentages in the S phase (28.97%) and G2/M phase 
(17.1%). DMSO (0.01%) samples did not show a significant change compared to 
vehicle control samples. Following SFN treatment, the percentage of cells in the S 
phase increased in the 1.25 and 2.5µM samples to 42.39% and 42.35%, which was a 
significant change compared to control and DMSO samples. The 5µM samples of 
one batch were lost, therefore a statistical significance compared to control or 
DMSO samples could not be calculated. Although SH-SY5Y showed a similar 
tendency, we only present a single observation and thus this experiment would 
need to be repeated (see appendix p.141, Figure 53). 
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Figure 15: Cell cycle assay of SFN in PC-12 cells. 
Cells were exposed to media only, DMSO (0.01%) or different concentrations of 
SFN for 24h. The distribution of cells in different cell cycle stages was obtained by 
flow cytometry and FlowJo software. A shows sample figures with SFN 
concentrations from 1.25µM-10µM,, while B displays the average of 3 biological 
replicates of samples ranging 0.625-5µM SFN (n=3, unless otherwise marked; ±SD;              
.   P<0.02 vs control,      P<0.02 vs DMSO). 
 
#   * 
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3.2.3  EFFECT OF SULFORAPHANE ON PHASE I I  AND ANTIOXIDANT ENZYME 
EXPRESSION 
First, 18S rRNA was assessed to be a suitable reference gene in PC-12 cells by using 
the GeNorm Kit provided by Primer Design (data not shown). After a 4h treatment 
with media only, DMSO (0.01%) or 5µM SFN, RNA was extracted, transcribed to 
cDNA and quantified via Taqman. This experiment was carried out in 4 biological 
and 2 technical replicates. 18S rRNA was amongst the most stable reference targets 
and was therefore used throughout all qPCR experiments. 
Nrf2 nuclear protein levels in PC.12. Nrf2 levels of nuclear protein were investigated 
over a variety of time points. At 2h, Nrf2 protein levels showed a 3 fold induction for 
5µM and 10µM SFN treatments (Figure 16). Individual blots show a visible increase of 
protein expression from DMSO controls up to 10µM SFN. A dose dependent trend 
can be seen in an accumulated graph, showing 4 individual time points (see 
appendix Figure 55, p.143). 
SFN on TR-1 gene expression in PC-12. Results in Figure 17 show a dose dependent 
increase in TR-1 expression on RNA level. After a 4h treatment with 2.5µM SFN, a 2.7 
fold increase was determined, while a 3.3 fold increase was found for 5µM 
treatment. 10µM SFN presented a 3.1 fold increase. HBSS, a positive control of 
autophagy, halves TR-1 levels compared to control, indicating no involvement of 
the autophagic pathway in the induction of TR-1 levels by SFN. These results only 
reflect the average of two biological replicates. 2h and 6h samples were also 
investigated in single biological replicates, which also showed an increase in TR-1 
expression in all SFN-treatment samples, the lowest in 2h samples (see Appendix 
Figure 56, p.144). Figure 18 presents a similar picture in protein expression, where the 
increase was strongest at 5µM SFN concentration after a 24h treatment with SFN. 
SFN on HO-1 protein expression in PC-12. Results presented in duplicates show a 
several fold increase of HO-1 protein levels when cells were treated with 10µM (5 
fold) and 20µM (25 fold) SFN for 24h. Lower concentrations (2.5µM and 5µM SFN) 
only produced minor change (Figure 19). This antibody presented itself as a dimer. 
Hardly any bands were visible at the expected size of 30-33kDa, however, at 
~60kDa strong bands could be detected. This phenomenon has been described 
within the antibody data sheet, but also by Hwang et al. (2009) documenting that 
HO-1 is in fact more stable and functions better as a dimer/oligomer in the ER.  
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SFN on GST gene expression in PC-12. 4hour treatment with SFN shows a 6-8 fold 
increase in 2.5, 5 and 10µM treatments, however in a non-dose dependant manner 
(Figure 20). HBSS, a positive control for autophagy, showed a decrease in GST levels, 
suggesting that autophagy does not play a role in the induction of GST by SFN, as 
would be expected. These results only reflect the average of two biological 
replicates. 2h and 6h samples were also investigated in single biological replicates, 
which showed a lower induction of GST by SFN (see Appendix Figure 57, p.145).  
SFN on TR-1 and GST gene expression in SH-SY5Y. In SH-SY5Y cells, 2h exposure to 
SFN could not elevate TR-1 levels higher than 1.4-fold compared to control. 
However, after 6h of SFN treatment induction of up to 3.2 fold (2.5µM SFN) could be 
observed (see Appendix Figure 58, p.145). Looking at GST levels, a dose-dependent 
response was observed. The lowest SFN concentrations presented a 2-fold increase 
compared to control samples both after 2 and 6 hours (see Appendix Figure 59, 
p.146). The highest induction of GST gene expression levels was found in the 2hour 
sample of 5µM SFN treatment. These experiments were only carried out with one 
biological replicate, as they were preliminary investigations only, and therefore 
would need further repeats to be of significant value. 
Short interfering RNA (siRNA) was introduced to mimic a knock down of both GST 
and TR-1, and an optimal dosage of 10nM siGST and siTR-1 could be determined by 
qPCR to be used in future experiments on cell protective effects of SFN in GST or 
TR-1 reduced PC-12 cells (data not shown).  
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Figure 16: Nrf2 expression in PC-12 cells after 2h SFN treatment as 
determined by western blot. 
PC-12 cells were treated with DMSO (0.02%) or various concentrations 
of SFN (2.5-10µM) for 2h. Nuclear protein was collected and blots were 
imaged using Odyssey. The graph shows the average of two 
biological replicates (n=2; ±SD). 
 
 
Figure 17: TR-1 expression in PC-12 cells after 4h SFN treatment as 
determined by qPCR. 
Cells were treated with media alone, DMSO (0.02%), HBSS and different 
concentrations of SFN (2.5-10µM) for 4h. 18S rRNA was used as 
housekeeping gene. Bars show qPCR results as fold change compared 
to control samples. Each bar represents the average of two biological 
replicates carried out in 3 technical replicates (n=2). 
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Figure 18: TR-1 expression in PC-12 cells after 24h SFN treatment as determined 
by western blot. 
Cells were treated with media alone, DMSO (0.01%), or various 
concentrations of SFN (2.5-10µM) for 24h. The blots were imaged by Odyssey 
and show TR-1 bands at 55kDa and loading control β-actin at 42kDa. The bars 
represent the average of both biological replicates shown in the western 
blots (n=2, ±SD). 
 
 
Figure 19: HO-1 expression in PC-12 cells after SFN treatment as determined by 
western blot. 
Cells were treated with control media, DMSO (0,01%) or different SFN 
concentrations and incubated for 24h. The blots were imaged by Odyssey 
and show HO-1 bands at 60kDa and loading control β-actin at 42kDa. The 
bars represent the average of both biological replicates shown in the western 
blots (n=2; ±SD). 
 
Chapter 3 | Sandra Bednar 
 
p a g e  74 of 156 
 
 
Figure 20: GST expression in PC-12 cells after 4h SFN treatment as determined by 
qPCR. 
Cells were treated with media alone, DMSO (0.02%), HBSS or various 
concentrations of SFN (2.5-10µM) for 4h. 18S rRNA was used as housekeeping 
gene. Bars show qPCR results as fold change compared to control samples. Each 
bar represents the average of two biological replicates, carried out in 3 technical 
replicates (n=2; ±SD). 
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3.2.4  SULFORAPHANE AND AUTOPHAGY 
Several experiments were carried out to investigate the effect of SFN on PC-12 and 
SH-SY5Y cells in relation to autophagy. For western blotting, a reliable method using 
the Odyssey imaging technique was developed (see page 53). The main target 
investigated is LC3-II, an autophagy related protein necessary for autophagosome 
formation. It is derived from LC3-I by the use of Atg7 and Atg3 (more detail on page 
38). Also, transient transfections with various plasmids connected to autophagy 
were carried out. 
Effect of SFN on LC3-II in PC-12 cells. SFN induced LC3-II protein levels in western blot 
experiments. The optimal dose, determined by a dose-response experiment was 
10µM, which was taken further into a time-response experiment (Figure 21). 20µM 
showed a greater effect (5 fold induction), however, at this concentration there is 
also the risk of reducing cell viability. The results of this experiment suggests that 3 
hours was the most effective treatment time to observe LC3-II induction in PC-12 
cells (data not shown). 
Effect of SFN on p62 expression in PC-12 cells. Figure 22 shows a time-dependent 
induction of p62 protein levels after treatment with 5µM SFN. However, the positive 
controls for autophagy torin and HBSS reduce p62 levels, showing the opposite result 
to that observed in SFN-treated samples. This can be explained by the fact that p62 
also interacts with Nrf2, another major target of SFN (explained in more detail on 
page 42). By taking into account the rise of p62 through the positive feedback loop 
with Nrf2 and SFN inducing Nrf2 however, one should expect p62 levels to rise in the 
presence of SFN. This makes it difficult to interpret the results on p62 levels, as it does 
not clearly state that autophagy is present. 
Effect of SFN on LC3-II in SH-SY5Y cells. In Figure 23, a dose-dependent induction of 
LC3-II protein levels was observed. Even levels as low as 5µM SFN show a 3-fold 
increase, gradually rising to almost 23-fold (mean) activation in 20µM SFN samples.  
Effect of SFN on p62 in SH-SY5Y cells. As explained above in PC-12 cells, SFN does 
not show the expected results in relation to autophagy. This can also be seen in 
Figure 24, as a clear dose-response from 2.5µM to 20µM SFN can be seen after 24h 
treatment, resulting in almost 25-fold increase compared to control samples. The 
high variability in the data within the 4 biological replicates means that the results 
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are not statistically important, although in one 20µM sample a 62-fold increase was 
observed compared to the control. 
 
 
 
 
Figure 21: LC3-II expression in PC-12 cells as determined by western blot. 
Cells were cultured either in media alone, in DMSO (0.05%) or in various concentrations of 
SFN (2.5-20µM) for 17h. The blots were imaged using Odyssey and show LC3-I bands at 
18kDa, LC3-II at 16kDa and loading control β-actin at 42kDa.The graph shows the 
quantification of LC3-II after normalisation with β-actin expressed as fold change 
compared to control. The bars represent the average of 3 blots (n=3, ±SD).  
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Figure 22: p62 expression in PC12 cells as determined by sestern blot. 
Cells were cultured either in DMSO (0.05%), Torin (250nM), HBSS or 5µM SFN for 4, 8, 
12 and 24h. The blots were imaged using Odyssey and show p62 bands at 62kDa 
and β-actin at 42kDa. The graph shows the quantification of p62 after 
normalisation with β-actin expressed as fold change compared to DMSO control. 
The bars represent the average of 2 blots (n=2, ±SD). 
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Figure 23: LC3-II expression in SH-SY5Y cells after a 24h treatment with SFN as 
determined by western blot. 
A Cells were cultured in media, DMSO (0.02%) or various concentrations of SFN 
(2.5-20µM) for 24h. Appropriate amounts of DMSO were added to each SFN 
sample to adjust for equal amounts. The blots were imaged by Odyssey and show 
LC3-I bands at 18kDa, LC3-II at 16kDa and loading control β-actin at 42kDa.           
B shows the quantification of LC3-II after normalisation against β-actin. Each bar 
represents the average of 4 biological replicates (n=4; ±SD). Statistical significance 
compared to control samples *, or to DMSO samples ** (P<0.05). 
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Figure 24: p62 expression in SH-SY5Y cells after a 24h treatment with SFN as 
determined by western blot. 
A Cells were cultured in media, DMSO (0.02%) or various concentrations of SFN (2.5-
20µM) for 24h. Appropriate amounts of DMSO were added for adjustment of equal 
DMSO amounts. The blots were imaged by Odyssey and present p62 bands at 
62kDa and the loading control β-actin at 42kDa. B Each bar represents the 
average of 4 biological replicates after normalisation against β-actin (n=4; ±SD) 
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Bafilomycin experiment. To assess the autophagic flux, the lysosome-inhibitor 
bafilomycin (BAF) was added either alone or in combination with SFN. The results 
presented in Figure 25 show that samples treated with BAF mostly induce LC3-II 
production. SFN on its own moderately increases LC3-II levels, while the 
combination of BAF and SFN can induce LC3-II bands between 4 and 12 fold in 4h 
and 8h treatments compared to control samples only treated with DMSO. These 
observations indicate that SFN mostly induces autophagy by enhancing 
autophagosome synthesis, but also increases autophagosome degradation, which 
explains the reduced or unchanged LC3-II levels after only SFN treatment. As these 
findings are simply momentary observations of the dynamic process autophagy, 
the results can only verify that SFN is inducing autophagy and suggest that increase 
of autophagosome synthesis plays the major role in the mechanism involved.  
Transient transfections on PC-12 cells. The clearest results to visualize the autophagic 
process were obtained by the transfection with the p62-tomato red and mRFP/GFP-
LC3 plasmids.  
p62-transfected cells show increased punctae-formation from 2.5, 5 and 10µM SFN 
treated cells Figure 26. These punctae represent autophagosomes, in which p62 is 
present until degraded within the autolysosome. In this experiment, induced p62-
levels are already present after 4 hours. 
The tandem- or traffic light- plasmid mRFP/GFP-LC3 helps elucidate a time pattern 
for the autophagic process. Figure 27 shows the images obtained after 4 hour 
treatment with media only, DMSO in media, HBSS or 2.5, 5 and 10µM SFN. As the 
punctae seen in this figure are all orange, and also the separate channels GFP and 
mRFP seem to overlap, there does not appear to be any autolysosome formation 
present.  
 
 
 
 
A 
B 
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Figure 25: Bafilomycin (lysosome inhibitor) on PC-12 cells. 
Cells were cultured in either DMSO (0.05%), 100nM bafilomycin (BAF; lysosome 
inhibitor), 5µM SFN or the combination of BAF and SFN for 2, 4 or 8 ours. The blots 
were imaged by Odyssey and show LC3-I bands at 18kDa, LC3-II at 16kDa and 
loading control β-actin at 42kDa. The graph shows the quantification of LC3-II 
after normalisation against β-actin expressed as fold change compared to 
vehicle control (0.05% DMSO). Each bar represents the average of 4 biological 
replicates (n=4; ±SD). 
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Figure 26: Transient Transfection of PC-12 cells with p62 tomato red plasmid. 
Cells were cultured for 4 hours in either media alone, DMSO (0.025%), HBSS or 
various concentrations of SFN (2.5-10µM). DMSO was added where necessary to 
reach equal amounts. The scale bar shows 10µm. 
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B 
Figure 27: Transient transfection on PC-12 cells with mRFP/GFP-LC3 plasmid. 
Cells were cultured for 4 hours in either media, DMSO (0.025%), HBSS, or various 
concentrations of SFN (2.5-10µM). DMSO was added to SFN samples when 
necessary to reach equal amounts. Pictures shown represent 100x magnification 
under the fluorescent microscope, scale bars show 10µm. The top 2 rows show 
merged images, while the nest two rows only present the green or red channel, as 
indicated. 
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3.2.5  NEUROPROTECTIVE EFFECTS OF SULFORAPHANE ON PC-12, DIFF PC-12 
AND SH-SY5Y CELLS 
3.2.5.1  SULFORAPHANE ON APOPTOSIS 
Dose-dependent increase of apoptosis by SFN in PC-12 cells. A preliminary 
experiment was conducted to measure the effect of SFN on apoptosis in PC-12 
cells and determine a concentration of SFN to use for further experiments. The 
AnnexinV/PI Flow Cytometry results (see appendix Figure 60, p.147; gating see 
Figure 51, p.138) show that 1.25, 2.5, 5 and 10µM SFN increases apoptosis in a 
dose-responsive manner. It was decided to use 2.5µM SFN in future experiments. 
3.2.5.2  NEUROPROTECTIVE EFFECTS OF SULFORAPHANE ON PC-12 CELLS 
Cell-protective effect of SFN against H2O2-induced apoptosis in PC-12 cells. H2O2 
was used to induce apoptosis and investigate if SFN pre-treatment can protect 
these cells (Figure 28; gating see Figure 49; p.136). 600µM H2O2 reduced cell viability 
to 40% and 800µM H2O2 to 35%, on average. SFN-pre-treated samples increased the 
numbers of viable cells to 63% and 61%, respectively. The average recovery rate 
was 25% for both 600 and 800µM H2O2 samples. However, the standard deviation 
hides the great differences that could be seen within individual data sets (see 
appendix Figure 61, p.148), which can be explained by slightly different confluency 
stages at the start of the experiments. From this point onwards, experiments were 
seeded and treated at the exactly same time in the day to increase experiment 
reliability.  
Cell-protective effect of SFN against 6-OHDA-induced apoptosis in PC-12 cells. Cells 
pre-treated with 2.5µM SFN show a higher resistance against 6-OHDA (another 
cytotoxin and ER-stress inducer) than untreated. Figure 29 shows the percentage of 
events in the healthy cells gate (AnnexinV-/PI-) (gating see Figure 50, p.137). 600µM 
6-OHDA reduced the percentage to 34,97%, 800µM 6-OHDA even to 21,75%. Cells 
pre-treated with SFN however presented 50.99% (+600µM 6-OHDA) and 38.76% 
(+800µM 6-OHDA) in an average of 6 biological replicates, which is a recovery of 
15,74% and 17,57% with P<0,01. 
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Figure 28: Effect of SFN on H2O2-induced apoptosis in PC-12 cells measured by flow 
cytometry. 
Cells were pre-treated with either DMSO (0.025%) or 2.5µM SFN for 24h. Then these 
solutions were replaced with either serum-free media, 600µM or 800µM H2O2 for 
another 24h. The collected samples were analysed using the AnnexinV/PI kit and 
a flow cytometer. Bars are the average of 4 biological replicates with about 
10.000 events each (n=4; ±SD). 
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Figure 29: Effect of SFN on 6-OHDA-induced apoptosis in PC-12 cells measured by 
flow cytometry. 
Cells were pre-treated with 0.025% DMSO or 2.5µM SFN for 24h and then treated with 
either serum-free media or 6-OHDA (600 and 800µM) in serum free media. Each bar 
shows the percentage of viable cells and represents the average of 6 biological 
replicates with 10.000 events each (n=6; ±SD; ***P<0.01). 
Chapter 3 | Sandra Bednar 
 
p a g e  86 of 156 
 
3.2.5.3  NEUROPROTECTIVE EFFECTS OF SULFORAPHANE ON DIFF PC-12 CELLS  
Cell-protective effect of SFN against H2O2-induced apoptosis in PC-12 cells. Cells 
pre-treated with 2.5µM SFN show a higher resistance against H2O2 than untreated. 
Figure 30 shows the percentage of events in the healthy cells gate (AnnexinV-/PI-). 
Cells pre-treated with SFN reduced the percentage of apoptotic cells induced by 
300µM H2O2 highly significantly (P<0.01), while SFN rescued cells exposed to 500µM 
H2O2 significantly (P<0.02).  
3.2.5.4  NEUROPROTECTIVE EFFECTS OF SULFORAPHANE ON SH-SY5Y CELLS 
Cell-protective effect of SFN against H2O2-induced apoptosis in SH-SY5Y cells. 
AnnexinV/PI assays have also been carried out on SH-SY5Y cells showing minor 
cytoprotection (data not shown). 
 
 
Figure 30: Effect of SFN on H2O2-induced apoptosis in DIFF PC-12 cells measured by 
Flow Cytometry. 
Cells were pre-treated with media or 2.5µM SFN for 24 hours and then treated 
with either serum-free media, 300 or 500µM H2O2 in serum-free media. Each bar 
shows the percentage of gates of viable cells and represents an average of 4 
biological replicates with 10.000 events investigated by AnnexinV/PI (n=4; 
**P<0,01; *P<0,02). 
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3.3 SUMMARY 
The data presented in this chapter confirm that SFN has similar effects on neuronal 
cells as previously reported on other cell lines (see 1.1.5). 
The effects of SFN on the cell cycle in PC-12 and SH-SY5Y cells suggest a dose-
dependent increase in the S-phase of the cell cycle, while results in DIFF PC-12 could 
not be obtained due to polyploidy (data not shown). This however is an indirect 
confirmation that the PC-12 cells have actually differentiated (Ignatius et al. 1985).  
In PC-12 cells SFN also increased nuclear protein levels of Nrf2 as well as the Nrf2/ARE 
driven enzymes GST and TR-1 at mRNA levels and HO-1 on protein level.  
SFN dose-dependently induces autophagy and apoptosis in PC-12 and SH-SY5Y 
cells. Autophagy was measured by LC3-II and p62 formation at a protein level, 
transient transfections with autophagy-related plasmids as well as LC3 flux. A 
positive feedback loop between Nrf2 and p62 lead to an increase of p62 samples 
rather than a reduction. Torin and HBSS were used as positive autophagy controls.  
An experiment to assess autophagic flux assessed that SFN is likely increasing LC-II 
levels by enhanced autophagosome formation rather than by inhibition of its 
degradation.  
Further, results of apoptosis assays have shown cell protective properties of SFN 
against H2O2- and 6-OHDA- induced apoptosis in all three cell lines at low dose.  
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4 EFFECT OF SULFORAPHANE ON 
THE EXPRESSION OF DJ-1 AND 
ER-STRESS 
4.1 INTRODUCTION 
DJ-1, or PARK7, is a multifunctional protein associated with Parkinson’s disease (PD) 
pathogenesis. It contains 189 amino-acids and belongs to the Thi/PfpI protein 
superfamily (Gan et al. 2010). DJ-1 possesses antioxidant capabilities, but has also 
been associated with cancer. When mutated, it has been linked to recessively 
inherited Parkinson’s Disease (PD), while wildtype DJ-1 has been shown to protect 
neuronal cells by removing H2O2 in response to oxidative stress (Rannikko et al. 2012; 
Bandopadhyay et al. 2004). The lack of DJ-1 has also been associated with COPD, 
which is a disease that presents a decline in Nrf2-regulated antioxidants (Malhotra 
et al. 2008). DJ-1 is highly expressed in human brain cells (Bandopadhyay et al. 
2004). 
Choi et al. (2006) observed that DJ-1 was irreversibly oxidised in brains of patients 
with idiopathic AD and PD. Brain tissues from five PD cases and five AD cases 
showed an increase in total DJ-1 protein compared to five healthy non-demented 
control subjects, especially in the acidic isoforms of the monomer of DJ-1. Also, 
cysteine and methionine oxidation of DJ-1 could be detected in PD and AD 
samples (Choi et al. 2006). 
Studies on DJ-1-deficient mice have shown indistinct motor deficits and minor 
nigrostriatal dopaminergic dysfunctions as well as higher sensitivity towards some 
toxins, but interestingly none of the mice from these studies presented 
characteristics of PD  such as loss of dopaminergic neurons, nor any major 
behavioural phenotype (Henchcliffe & Beal 2008; Pham et al. 2010). Possibly 
unknown mechanism take over the role of DJ-1 to protect healthy animals against 
the loss of DJ-1. Pham et al. (2010) undertook further research and found that DJ-1 
knockout (KO) mice demonstrated a reduction in dopamine-producing neurons in 
the ventral tegmental area as well as minor changes in behaviour, for instance 
motivational and cognitive dysfunction. Lastly, this study also shows that these KO 
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mice exhibit different measures to compensate the lack of DJ-1, which may be the 
reason no more severe phenotypes were observed - supporting the hypothesis of 
PD being a multifactorial disease. 
Many reports have found a correlation between the absence of DJ-1 and 
increased vulnerability to toxins. Lev et al. (2013) used DJ-1 KO mice to demonstrate 
enhanced sensitivity towards 6-OHDA insults compared to wild-type (WT) 
astrocytes. The DJ-1 KO showed a lower ability to counteract 6-OHDA-induced 
oxidative stress via the cellular mechanisms Nrf2 and HO-1. Also, the activation of 
the Nrf2 pathway appeared impaired in DJ-1 KO astrocytes compared to WT (Lev 
et al. 2013).  
DJ-1 is understood to be an important stabiliser of Nrf2 after its dissociation from 
Keap1 (Clements et al. 2006). Another, more recent study has suggested the 
activation of Nrf2 to be downstream from DJ-1, and that the DJ-1/Nrf2/TR1 interplay 
is important in the cellular response to oxidative stress (Im et al. 2012). Contradictory 
to these reports, Gan et al. (2010) found the Nrf2/ARE pathway to be independent 
of DJ-1. They demonstrated that the Nrf2 activator tBHQ was able to protect primary 
cortical neurons from DJ-1 KO as well as WT mice. Yokota et al. (2003) investigated 
the mechanisms of neuronal cell death caused by absence or mutations of DJ-1 
and found oxidative stress, ER stress and proteasome inhibition to be the inducers 
that can be influenced by DJ-1. Ziaei et al. (2013) showed that SFN could increase 
DJ-1 protein levels in primary corneal endothelial cells obtained from patients 
suffering from Fuchs endothelial corneal dystrophy. These cells demonstrated a 
lower expression of DJ-1 than regular corneal endothelial cells, however, after SFN 
treatment protein expression was improved. Their conclusion was that Nrf2 and DJ-1 
were acting dependant of each other, but their results did not answer which of the 
two is the instigating part. 
Although a few other research groups have briefly mentioned DJ-1 in context of 
SFN, none have investigated this relationship in depth. Our aim was therefore to 
investigate the influence SFN has on DJ-1, if it can protect PC-12 cells from ER-stress 
and if DJ-1 is connected to that. 
Figure 31 shows the presumed relationship between SFN, DJ-1, Nrf2 and autophagy, 
based on several publications (Clements et al. 2006; Im et al. 2012).  
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Figure 31: SFN/Nrf2/autophagy graph including DJ-1 
This simplified graph shows how DJ-1 fits into the SFN/Nrf2/autophagy pathway. It 
only shows the SFN-triggered pathway. SFN can bind to Keap1 by interacting with 
the thiol groups of cysteine residing in Keap1 to impair the ubiquitination of Nrf2. 
With the assistance of DJ-1, Nrf2 then translocates into the nucleus, where it binds to 
the ARE of cytoprotective genes like GST and HO-1. SFN also increases autophagy, 
a process that degrades p62 as part of the protein degradation process. However, 
p62 can also be upregulated by Nrf2, thus binding more Keap1 and, by keeping 
Keap1 occupied, increasing the amount of free Nrf2 in the cytoplasm.  
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4.2 RESULTS 
4.2.1  INDUCTION OF PROTEIN LEVELS OF DJ-1 
Western Blots with total protein as well as cytosolic protein showed that SFN could 
increase DJ-1 expression in a dose dependent manner. Different SFN-treatment 
times were investigated to optimise future experiments (Figure 32, more single 
replicate western blots can be found in the Appendices Figure 62).  
 
 
Figure 32: DJ-1 expression in PC-12 cells after SFN treatment as determined by 
western blot. 
Cells were treated with 0.02% DMSO (vehicle control) or different SFN 
concentrations and incubated for 24h. The blots were imaged using Odyssey 
and data calculated from DJ-1 bands (23kDa) against β-actin (42kDa). The bars 
represent the average of two biological replicates, the western blot at the 
bottom shows one of them. 
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4.2.2  INFLUENCE OF SULFORAPHANE ON CHOP EXPRESSION UNDER ER-STRESS 
First, the ideal concentration of tunicamycin, which is a mixture of homologous 
antibodies (containing uracil, N-acetyl glycosamine, tunicamine and a fatty acid) 
and a well-known ER-stress inducer, was ascertained by western blot against the 
antibody CHOP. CHOP (C/EBP homologous protein) is a protein expressed during 
ER-stress-mediated apoptosis and is therefore a good marker to measure ER-stress. 
SFN did not induce CHOP levels thus ER stress, but both 0.5 and 1µg/ml tunicamycin 
increased CHOP levels at 4h as well as 24h. As this was a basic assessment with sole 
intention to see if tunicamycin could in fact induce ER-stress and that SFN does not, 
a single biological replicate seemed adequate. It was determined that a 4h 
incubation with 1µl/mg tunicamycin is sufficient to increase CHOP levels 
considerably compared to tunicamycin-free samples (Figure 33).  
SFN did not change the tunicamycin-free levels, which were barely detectable, 
however, it was able to reduce the CHOP levels showing the tunicamycin induced 
ER-stress significantly. This could be seen for protein levels (Figure 35) as well as RNA 
levels (Figure 35). 
In addition, 6-OHDA was applied as an alternative ER-stress inducer, in which SFN 
also was able to reduce resulting CHOP levels significantly (Figure 36). 
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Figure 33: CHOP expression in PC-12 cells after SFN and tunicamycin treatment 
as determined by western blot.  
PC-12 cells were treated with either 0.02% DMSO, 2.5 or 10µM SFN or 0.25, 0.5 
and 1µl/mg tunicamycin for either 4h or 24h. The blots were imaged by 
Odyssey and show CHOP bands at 27kDa and actin at 42kDa. The graph 
shows the quantification of CHOP after normalisation with β-actin expressed 
as fold change compared to the vehicle control DMSO at each time point. 
Each bar represents the one biological replicate shown in the blot below. 
 
 
 
Figure 34: CHOP expression in PC-12 cells after SFN pre-treatment followed by 
tunicamycin exposure as determined by PCR. 
PC-12 cells were treated with 0,02% DMSO or 5µM SFN for 24h prior to a 4h 
exposure to either DMSO or 1µg/ml tunicamycin. RNA extractions were 
transcribed into cDNA and then run on an agarose gel before being 
visualised under UV light. 
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Figure 35: CHOP expression in PC-12 cells after SFN pre-treatment followed by 
tunicamycin exposure as determined by western blot. 
PC-12 cells were treated with 0.02% DMSO or 5µM SFN for 24h. This was replaced 
1µg/ml tunicamycin or DMSO for a further 4h exposure. The blots were imaged 
by Odyssey and show CHOP bands at 27kDa and actin at 42kDa. The graph 
shows the quantification of CHOP after normalisation with β-actin expressed as 
fold change compared to the vehicle control DMSO of tunicamycin treated 
cells. Each bar represents an average of 5 biological replicates. 
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Figure 36: CHOP expression in PC-12 cells after SFN pre-treatment followed by 
6-OHDA exposure as determined by western blot. 
PC-12 cells were treated with 0.01% DMSO or 5µM SFN for 24h. This was 
replaced by 800µM 6-OHDA in serum-free media or just serum-free media for 
a further 4h exposure. The blots were imaged using the Odyssey and show 
CHOP bands at 27kDa and β-actin at 42kDa. The graph shows the 
quantification of CHOP after normalisation with β-actin expressed as fold 
change compared to the vehicle control DMSO. Each bar represents an 
average of 3 biological replicates. ** P<0.02%. 
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4.2.3  EFFICIANCY OF DJ-1 KNOCK DOWN USING SIRNA 
siDJ-1 was used to simulate DJ-1 knock down in PC-12 cells. The efficiency of this 
siRNA was then tested with western blot (Figure 37, B). Although the blot shown 
indicates that siDJ-1 can reduce DJ-1 levels in SFN-treated tunicamycin-free as well 
as in DMSO-treated tunicamycin samples, this is not the case in any of the others 
within this data set. This inconsistency could be observed in follow-up experiments. 
The graph (Figure 37, A) shows that overall (n=4) no knock down could be 
established. 
10µM SFN might have been a better choice of concentration to see a proper 
induction of DJ-1. 3 of these experiments have been carried out on a lower passage 
number of PC-12 cells, which might be less sensitive to SFN. Due to time constraints 
these assay optimisation ideas could not be addressed.  
The protein collected from the siRNA experiments was also blotted against CHOP 
to see if DJ-1 is involved in the protective effects of SFN. However, due to the siRNA 
not showing a consistent knock down, these results are mere speculation. At least 
they confirm that SFN can significantly reduce tunicamycin-induced ER-stress (see 
Appendices Figure 64, graph only showing siRNA-free samples see Figure 35). 
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Figure 37: DJ-1 expression in PC-12 cells in siRNA knockdown conditions as 
determined by western blot. 
PC-12 cells were treated with siDJ-1 before starting a 24h incubation with 5µM 
SFN. This was replaced by 1µg/ml tunicamycin for another 4h, followed by protein 
extraction. A Blots were imaged using Odyssey and show DJ-1 bands at 23kDa 
and β-actin bands at 42kDa. B shows the fold change of normalised DJ-1 protein 
levels compared to All* DMSO controls. Each bar represents an average of 4 
biological replicates. 
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4.3 SUMMARY 
DJ-1 protein levels were elevated after 24h SFN treatment.  
ER-stress levels could successfully be induced by 1µg/ml tunicamycin at 4h. SFN  did 
not cause ER-stress, but in fact reduce ER-stress levels created by tunicamycin. This 
could be shown by investigating CHOP protein levels as well as RNA levels. The 
western blot results show a highly significant reduction in CHOP levels, while PCR gel 
results are clearly visible, but were not quantified. 
siDJ-1 results were inconclusive. DJ-1 was silenced to investigate any correlation 
DJ-1 has with ER-stress, and if SFN can still protect PC-12 cells when DJ-1 levels are 
diminished. Since none of the blots on DJ-1 to review the effectiveness of the siDJ-1 
showed consistent results, any changes observed when blotting against CHOP are 
negated. Thus, this experiment model needs improving. 
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5 THE ROLE OF AUTOPHAGY IN 
CELL PROTECTIVE MECHANISMS 
OF SULFORAPHANE 
5.1 BACKGROUND & AIMS 
Autophagy has become a popular research field in the recent years. This complex 
process, which is described in more detail on page 37, is responsible for the 
organised degradation of proteins and organelles through lysosomes as a response 
to nutrient limitation to maintain the homeostasis of the cell (Jo et al. 2014). Amongst 
others illnesses, impaired autophagy has also been connected to 
neurodegenerative diseases (Metcalf et al. 2012). Autophagy-inducing agents 
have already shown to have a beneficial therapeutic impact in various mouse 
models of different neurodegenerative diseases (Nixon 2013). 
First reports of SFN on autophagy were carried out in cancer cell lines. Herman-
Antosiewicz et al. (2006) investigated SFN on pancreatic cancer cell lines PC-3 and 
LNCaP. They found that SFN could upregulate autophagosome formation and the 
recruitment of LC3 while also inhibiting the cytosolic release of cytochrome c and 
apoptotic cell death. When autophagy inhibitor 3-MA was added, LC3 production 
was reduced and apoptosis upregulated. As cell death of cancer cells by apoptosis 
is one approach to eliminate cancer, this study focused on the enhancement of 
apoptosis by adding 3-MA. In the previous chapter 3 (page 65) we could show that 
SFN is able to induce autophagy in PC-12 and SH-SY5Y cells. This chapter 
investigates the possibility of autophagy being another important player in the 
protective effects of SFN. By knocking down or out a gene in autophagy, the effect 
of SFN cell survival can be tested in an autophagy-deficient or inhibited cell.  
First, the efficiency of the two autophagy inhibitors, 3-MA and wortmannin, are 
assessed. They both block the autophagosome formation by inhibiting PI3K (Triola 
2015). However, when knocking down pathways with chemical reagents, this 
pathway might find substitute routes to restore its activation. Does chemically 
induced autophagy deficiency reduce the protective effects of SFN against 
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apoptosis? The development of Atg16L1 KO mice enabled an alternative 
methodology to chemical inhibition. 
The protective effects or SFN was shown in many different scenarios and has mostly 
been linked to the activation of Nrf2 (Guerrero-Beltrán et al. 2012; Tarozzi et al. 2013). 
Through the liberation of phase II enzymes as a reaction to oxidative stress, the cell 
can break down the harmful intruders like H2O2, 6-OHDA or other cytotoxins. In the 
absence of Nrf2-driven enzymes, SFN is still able to protect cells, to an extent, from 
toxin-induced cell death, suggesting the involvement of other pathways, such as 
autophagy. 
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5.2 RESULTS  
5.2.1  NEUROPROTECTIVE EFFECTS OF SULFORAPHANE WITH PART INHIBITION OF 
AUTOPHAGY 
3-MA and wortmannin did not significantly inhibit autophagy in PC-12 cells. 
Western blots were carried out to investigate the inhibition efficiency of the 
autophagy inhibitors wortmannin and 3-MA (Figure 38 and Figure 39). Wortmannin 
was blotted against the autophagy marker LC3-II. 5µM SFN on its own increased 
LC3-II levels. However, when paired with wortmannin (100nM), it still showed a minor 
increase in LC3-II protein levels, meaning that autophagosome formation was still 
possible.  
A similar result could be observed with 3-MA (5mM). LC3-II levels were still 
significantly increased when 3-MA was given together with SFN. 
With both inhibitors, a wide variation occurred, which also suggests unreliability. 
Therefore, alternative methods might be more suitable to study the protective 
effects of SFN in an autophagy-free environment.  
SFN decreased H2O2-induced apoptosis in presence of 3-MA. Results suggest that 
SFN cannot rescue as many cells from H2O2-induced apoptosis in the presence of 
3-MA. Instead of increasing the number of healthy cells up to almost 90%, only 80% 
healthy cells could be measured (see Appendix Figure 65, p.153) However, due to 
the fact that autophagy could not be fully suppressed (as seen in Figure 39), these 
results were not explored further. 
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Figure 38: LC3-II expression in PC-12 cells after 24h treatment with SFN in presence 
of wortmannin. 
Cells were cultured in 0.04% DMSO, 5µM and 10µM SFN and/or 100nM 
wortmannin. The blots were imaged by Odyssey and present the LC3-I bands at 
18kDa, LC3-II at 16kDa and β-actin at 42kDa. The graph shows the quantification 
of LC3-II after normalisation against β-actin. Each bar represents the average of 
the bands of 2 biological replicates (error bars = SD; n =2)). 
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Figure 39: LC3-II expression in PC-12 cells after 24h treatment with SFN in presence 
of 3-MA 
Cells were cultured in DMSO, 5µM and 10µM SFN and/or 5mM 3-MA. The blots 
were imaged by Odyssey and present the LC3-I bands at 18kDa, LC3-II at 16kDa 
and β-actin at 43kDa. The diagram shows the quantification of LC3-II after 
normalisation against β-actin. Each bar represents the average of 5 biological 
replicates (error bars = SD; n =5; *P<0.05). 
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5.2.2  ATG16L1 KO PRIMARY NEURONAL CELLS FROM MOUSE EMBRYOS 
Number of KO samples. The Mendelian ratio estimates a 1:4 chance to receive an 
Atg16L1 KO mouse from two Atg16L1 +/- mice (Figure 40). 
 
Figure 40 Simple schematics of the breeding scheme for generating Atg16L1 KO 
mice.  
The red block indicates Atg16L1 KO mouse. The percentage under each mouse 
presents the Mendelian ratio expected. For simplicity, the PGK-Cre inheritance 
has not been shown in the second generation. 
Method development and optimisation. The technique had not been previously 
established in our lab, therefore, through a number of experiments, cell retrieval and 
plating as well as treatment conditions were optimised to minimise waste and 
produce the highest number of viable PNCs per experiment. Since Atg16L1 mice 
have only a small chance of surviving, and that only for a short number of days or 
weeks, it was considered unethical to grow them until birth (Arasteh 2012). Hence, 
primary neuronal cells had to be derived from embryos (E14-16) rather than pups. 
This limited the choices of methods as well as experimental settings, since cell 
numbers were low. Since embryos had to be collected and dissected individually 
to prohibit cell contamination, there was not sufficient time to count the cells before 
plating. Thus, PNCs of each embryo were simply plated in equal parts following a 
protocol sketched out in Figure 41, which resulted in a great data variation between 
embryos. 
Primary neuronal cells were grown as described in the methods. After 7-9 days, full 
differentiation was achieved (Figure 42). 
Immunostainings of Atg16L1 KO and WT PNCs. In WT PNCs punctae can be seen in 
SFN samples, depicted in red (Alexafluor 594 (Figure 43)). These punctae seen are 
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LC3 positive autophagosomes and therefore resemble activation of autophagy. In 
KO cells, stimulation with SFN did not show the same effect, suggesting that 
autophagy is not present in these cells. The p62-Alexa488 staining presented 
inconclusive, which could again be explained by the positive feedback loop 
between p62 and Nrf2.  
A vehicle control and a positive control for autophagy were added to strengthen 
these findings. HBSS and SFN samples both showed punctae formation, while they 
were absent in KO samples (Figure 44). Quantification of autophagosomes punctae 
could be carried out using IMARIS software. Thus, a comparison of ratios 
autophagosomes/cells was carried out to calculate significant increase in LC3 
punctae of HBSS- and SFN-treated samples compared to controls (Figure 45). These 
findings confirmed that autophagy was heavily impaired in Atg16L1 KO samples. 
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Figure 41 This graph shows a sketch of the retrieval of PNCs. 
First, the pregnant mouse was dissected. Next, the embryos were placed into PBS 
in individual wells. The brain was carefully removed and pipette mixed. After 
letting cells rest, the supernatant was removed, spun down and resuspended in 
media + 10% hormones. Cells had to be plated immediately. After genotyping to 
identify Atg16L1 KO samples, experiments were carried out. 
 
 
 
 
Figure 42: Example picture of PNCs after 7 growth days. 
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Figure 44: Images of stained PNCs against LC3-Alexa594 and DAPI. 
Atg16L1 KO and WT PNCs were plated for immunostainings. They were treated 
with regular media (+10% hormones), 0.01% DMSO, 2.5µM SFN or HBSS, a positive 
control for autophagy, for 4h. Then they were stained with DAPI (nuclear stain, 
blue) and LC3 (Alexafluor 594, red). Images taken on the microscope were then 
analysed using the IMARIS software, which detects and quantifies punctae (see 
red dots on grey background). 
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Figure 45: Quantification of LC3 punctae with IMARIS. 
Atg16L1 KO and WT PNCs were plated on coverslips for immunostainings. They 
were treated with only media (+10% hormones), 0.01% DMSO, 1.25µM SFN or HBSS, 
a positive control for autophagy, for 4h. Then they were stained for LC3 
(Alexafluor 594, red) and DAPI (nuclear stain, blue). Images were quantified using 
IMARIS software. Bars represent the average of 5 or 6 images analysed (For the 
WT HBSS sample only 4 images could be taken into account because of an 
extremely high outlier). * P<0.05 compared to Control; # P<0.05 compared to 
DMSO. 
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5.2.3  NEUROPROTECTIVE EFFECTS OF SULFORAPHANE IN ATG16L1 KO PRIMARY 
NEURONAL CELLS 
Finally, PNCs were set up for AnnexinV/PI flow cytometry. This method was first 
optimised. Results show that in WT samples, SFN is able to significantly increase cell 
survival of cells against H2O2-induced cell death. In KO samples, however, this 
protective effect could not be observed, as SFN could only marginally rescue the 
H2O2-treated cells (Figure 46A). As the cells of each PNC source were plated 
individually to separate WT and KO cells, some variation between different data 
sets could be expected. The standard deviation shown as error bars in the diagram 
does therefor not accurately reflect the change observed within a data set, so a 
table was added to present those numbers (Figure 46B). SFN can recover an 
average of 18.18% of cells in WT samples, compared to only 2.94% in KO PNCs.  
During data collection, two different populations could be detected, thus, the 
gating strategy for the AnnexinV/PI experiments in PNCs needed to be assessed 
differently than for the other cell lines that have been used for this project.  For better 
quantification, they were not only calculated as one, but also separately (Gating 
graphs see appendix Figure 66, Figure 67, Figure 68, p.154f). Unfortunately we did 
not have the time nor the tools to investigate this further. However, it could indicate 
that another cell type other than neuronal cells is also present.  
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Figure 46: Effect of SFN on H2O2-induced apoptosis in Atg16L1 KO and WT PNCs 
measured by Flow Cytometry 
A Cells were pre-treated with 0.01% DMSO or 1.25µM SFN for 24h and then treated 
with serum-free media or 100µM H2O2. The treatment was removed after 4h and 
replaced with regular medium. Samples were measured by flow cytometry. Each 
bar represents an average of 4 (KO) and 5 (WT) biological replicates with 5000 
events investigated by AnnexinV/PI (*P<0.05 compared to DMSO control, unless 
otherwise shown; ANOVA and post-hoc t-test/Bonferroni corrected). 
B This table shows the average of the difference in % of healthy cells between H2O2 
and SFN+H2O2 samples within individual biological samples (total population). 
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5.3 SUMMARY 
The autophagy inhibitors 3-MA and wortmannin showed reduced protective effects 
of SFN when given in combination with H2O2. However, western blots to assess the 
efficiency of these inhibitors depicted only partly suppression of the 
autophagosome formation and thus the autophagic pathway. Therefore, as an 
alternative method with most likely a better outcome, PNCs were plated from WT 
or Atg16L1 KO mouse embryos. 
After several optimisation steps, these PNCs were successfully grown. In addition, I 
was able to confirm absence of LC3 positive autophagosomes in Atg16L1 KO cells 
compared to WT when induced by either SFN or HBSS. This could be observed by 
immunostaining. Furthermore, AV/PI experiments indicate the involvement of 
autophagy in the neuroprotective effects of SFN in H2O2 induced cell death.  
AnnexinV/PI results showed two faintly different populations during event collection. 
Therefore the experiment was plotted as was, but also separated in those two 
groups of events. The top population resembled the result of the total population 
almost 1:1.  
Atg16L1 KO samples did not show any significant difference between controls and 
SFN pre-treated samples. Although presented with a low sample number, and 
although the carefully selected concentration of 100µM H2O2 only reduced the 
percentage of viable cells to 80%, WT samples did show that SFN could rescue PNCs 
from H2O2-induced cell death a significant amount. Due to the timely and costly 
procedure as well as availability of KO embryos, these findings could not be 
confirmed during the time at hand. 
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6 DISCUSSION AND FUTURE 
PERSPECTIVES  
6.1 EFFECT OF SFN ON CELL VIABILITY OF PC-12 CELLS 
To assess the bioactivity of SFN in neuronal cells, PC-12 and SH-SY5Y cells were 
selected as cell models. As PC-12 cells represented a novel target for SFN activity, 
cell viability of SFN on PC-12 cells was assessed and an IC50 of 36.9µM following 24h 
exposure to SFN was determined.  
Several recent publications have also reported the effect of SFN on PC-12 cells. 
Exposure to 1µM and 5µM SFN for 24h resulted in reduction of 6-OHDA induced 
cytotoxicity, and a dose- and time-dependent increase HO-1 and Nrf2 protein 
levels (C Deng et al. 2012). Deng et al (2012)  also reported that 6h pre-treatment 
with 5µM SFN decreased 6-OHDA induced ER-stress (Chang Deng et al. 2012). 
In a study described by Izumi et al. (2012), SFN was used as a positive ARE-activating 
control, at a dose of 3µM SFN applied for 9h.  Their preliminary results have shown 
that exposure to ≥10µM SFN over a period of 48h elicited cytotoxicity.  
Throughout the course of the research described in this thesis, doses of 0.625-20µM 
SFN have been used for varying periods of cellular exposure, as followed.  
6.2 EXPRESSION OF NRF2 AND NRF2/ARE-REGULATED ENZYMES IN 
PC-12 AND SH-SY5Y CELLS AFTER TREATMENT WITH 
SULFORAPHANE 
Experiments investigating the effect of SFN on PC-12 and SH-SY5Y demonstrated 
that SFN can induce the expression of Nrf2 and Nrf2/ARE regulated enzymes in both 
cell lines (see 3.2.3, p.70). This was quantified at the protein level by immunoblotting, 
and at the level of RNA by qPCR. These findings are in agreement with several 
previously (see introduction) or simultaneously conducted studies (C Deng et al. 
2012; Morroni et al. 2013). 
More recently, PC-12 cells have been used as a neuronal model to demonstrate 
the protective effects of SFN against 6-OHDA-induced cytotoxicity (C Deng et al. 
2012). Further experimental work reported in this thesis, and conducted in order to 
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understand the underlying mechanism by which SFN protects against 6-OHDA-
induced cell death, demonstrated that SFN could significantly reduce caspase-3 
activation and subsequent cell death, increase HO-1 expression, induce the 
translocation of Nrf2 into the nucleus, and activate PI3K/Akt. SFN has  also been 
reported to enhance HO-1 expression in BV2 microglial cells at a concentration of 
5-20µM when applied for 24h (Foresti et al. 2013). As noted previously, SFN protected 
SH-SY5Y cells against H2O2 and 6-OHDA-induced cytotoxicity, which was attributed 
to  observed increases in NQO1, GST and GR (glutathione reductase) (Tarozzi et al. 
2009). 
The application of SFN in a PD mouse model demonstrated protective effects 
against 6-OHDA induced neurotoxicity (Morroni et al. 2013). Mice were fed with 
5mg/kg SFN twice weekly for four weeks after a unilateral intrastriatal injection of 6-
OHDA, inducing PD-like symptoms. The reduction in motor and coordination 
functions as well as degeneration in dopaminergic neurons was ameliorated 
significantly by SFN. The authors hypothesised that expression of GST was involved 
in mediating these effects, as increases in GST protein levels were observed.  
The research presented in this thesis demonstrates that exposure to SFN can induce 
expression of Nrf2, GST, HO-1 and TR-1 in PC-12 and SH-SY5Y cells, as reported in 
other cell lines (Brooks et al. 2001; Dinkova-Kostova & Talalay 2008; Fimognari et al. 
2008).  
6.3 THE EFFECT OF SULFORAPHANE ON AUTOPHAGY MARKERS IN PC-
12 AND SH-SY5Y CELLS 
As described in chapter 3.2.4 (p. 75), an induction of autophagic markers could be 
observed in all cell lines using several different methods. Immunoblotting data 
indicated increased LC3-II protein levels following treatment with SFN, while the 
effect on p62 expression was unclear. Levels of p62 usually decreased following 
exposure to SFN for up to x hours, as it is degraded during the autophagy pathway. 
However, treatment with SFN for up to 24h resulted in a clear increase of p62 levels. 
This could reflect a positive feedback loop between Nrf2 and p62. p62 is degraded 
during autolysosome formation and therefore  decreased levels of p62 protein 
would be expected when autophagy is activated. However, p62 can also bind to 
Keap1, thus disrupting the association between Keap1 and Nrf2 and releasing Nrf2 
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into the cytosol. Subsequent translocation of Nrf2 into the nucleus results in Nrf2/ARE-
driven gene expression, including the expression of p62 since the ARE is present in 
the p62 promotor (Jain et al. 2010).  A diagram of the proposed molecular 
pathways is presented on page 44.  
SFN has been shown to increase LC3-II protein levels in previous studies, although to 
date none were conducted in PC-12 cells. Most experiments were performed using 
cells, where induction of apoptosis by SFN was the main focus of investigation. It 
was found several reported studies that by adding an autophagy inhibitor (3-MA or 
BAF), SFN-induced apoptosis could be increased in human prostate cancer, and 
breast cancer colon cancer cells (Herman-Antosiewicz et al. 2006; Kanematsu et 
al. 2010; Nishikawa, Tsuno, Okaji, Shuno, et al. 2010). 
In this thesis, an experiment using BAF to block the fusion and thus degradation of 
autophagosomes was used to assess whether SFN increased autophagosome 
formation or elicited inhibition of fusion and subsequent degradation (see chapter 
3.2.4, p. 81). This experiment was based on methodology proposed by Rubinsztein 
et al. (2009) by measuring LC3-II protein levels following cell treatment with a test 
compound, or with BAF, or with both combined; although a chemical may both 
enhance synthesis and decrease degradation simultaneously. In our study SFN 
appeared to primarily induce autophagy by increasing autophagosome synthesis, 
but SFN also activated autophagosome degradation. However, autophagy is a 
dynamic process and the methodology described in this thesis only examines single 
observations; future investigations should utilise live imaging to address this issue.  
Increased autophagosome formation following exposure to SFN was also observed 
after transient transfection of PC-12 cells with p62-tomato red and mRFP/GFP LC3 
plasmids (monomeric red fluorescence protein/green fluorescence protein; see p. 
82f).  GFP-LC3 fluorescence decreases in the acidic lysosomal environment, whilst 
mRFP-LC3 fluorescence does not (Kimura et al. 2007).  By using tandem fluorescent-
tagged LC3, the observed punctae, which correspond with the number of 
autophagosomes, can be separated to differentiate between autophagosomes 
before fusion (showing both mRFP-LC3 and GFP-LC3) and after fusion (showing only 
the mRFP signal). In the experiments described in Chapter 3.2.4 (p. 83), only 
overlapping red and green signals were detected, suggesting that at the time of 
measurement no autolysosome formation had occurred. 
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By combining live imaging with the tandem fluorescent tagged mRFP/GFP-LC3, the 
dynamic process of autophagy could similarly be divided into stages of pre- and 
post-lysosome fusion. 
6.4 THE EFFECT OF SULFORAPHANE ON CELL CYCLE ARREST IN PC-12 
AND SH-SY5Y CELLS 
Cultured PC-12 or SH-SY5Y cells treated with various amounts of SFN (0.625µM-5µM 
SFN in PC-12 and 2.5µM-20µM in SH-SY5Y cells) were harvested and analysed by flow 
cytometry to examine the effects of SFN on the cell cycle (see Chapter 3.2.2, p.68). 
A significant dose dependent cell cycle arrest in the S-stage was observed in PC-12 
cells, and this was also observed in one experiment conducted in SH-SY5Y cells. 
To date, SFN-modulated cell cycle arrest in either PC-12 or SH-SY5Y cells has not 
been reported in scientific literature. Previous reports of SFN-induced cell cycle 
arrest have described arrest mainly in the G2/M-phase, and occasionally in the S-
stage, but these experiments were conducted using cancer cell lines (Herman-
Antosiewicz et al. 2006; Matsui et al. 2007; Kanematsu et al. 2010; Pawlik et al. 2013). 
In cancer cells, cell cycle arrest often results in subsequent p53-mediated cell death 
(Vermeulen et al. 2003). In neuronal cells however, neurodegeneration is 
associated with the activation of the cell cycle, and inhibition of cell cycle proteins 
such as cyclin-dependent kinases can increase neuroprotective effects (Kruman et 
al. 2004). Thus, SFN-induced cell cycle arrest as described in Chapter X could be 
interpreted as a protective effect l for cell function. This could be analysed further 
by examining the effect of SFN upon expression of cell-cycle related proteins such 
as cyclin-dependent kinases. 
6.5 NEUROPROTECTIVE EFFECTS OF SULFORAPHANE IN PC-12, DIFF 
PC-12 AND SH-SY5Y CELLS 
The protective effects of SFN against H2O2 and 6-OHDA-induced cell death was 
assessed by Annexin V/PI flow cytometry, as well as MTT assays (data not shown). In 
all cell lines, increased cell survival was detected, which in PC-12 and DIFF PC-12 
cells was highly significant (see Chapter 3.2.5, p.84). 
Mitochondrial membrane potential has been reported to regulate a cytochrome c 
induction in apoptosis (Gottlieb et al. 2003). To investigate if a reduction in 
depolarisation of mitochondrial membranes was involved in the cytoprotective 
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effect of SFN, a JC-1 experiment was conducted as described in Chapter X. JC-1 is 
a fluorescent probe, which emits a green-orange fluorescence in cells with normal 
polarised mitochondrial membranes, while in depolarised mitochondrial 
membranes it emits only green fluorescence. This can be observed in a 
fluorescence plot by a shift from the FL-1+/FL-2+ to right to the FL-1+/FL-2- bottom right. 
This has previously been observed for SFN in the human myeloid leukaemia cell line, 
amongst other cell lines, however not to a very strong extent  (Jana Jakubikova et 
al. 2005). The results described in the appendix (p. 139) did not reveal the expected 
shift towards the green fluorescence, so it could not be determined whether SFN 
modulated the mitochondrial membrane potential. However, protective effects 
could be observed (p.139; Raw data not shown). 
Other studies have also described a positive effect of SFN on neuronal cell function 
(Guerrero-Beltrán et al. 2010). Vauzour et al. (2010) demonstrated that cortical 
neurons had an increased rate of cell survival against 5-S-cysteinyl-induced toxicity 
when pre-treated with SFN. These authors also reported that expression of NQO1 
and other detoxification enzymes was induced by SFN. 
However, most reported studies have examined the effect of SFN on Nrf2 regulated 
genes, but have not investigated the complexity of potential SFN bioactivity.  
6.6 INDUCTION OF DJ-1 BY SULFORAPHANE IN PC-12 CELLS 
Research presented in Chapter 4.2.1 (p.91) of this thesis demonstrates that SFN is 
able to increase DJ-1 protein levels after a 24h exposure to 2.5, 5 and 10µM SFN. 
DJ-1 is a multifunctional protein, and mutations of DJ-1 have been associated with 
the development of PD. To date, only a few research groups have investigated DJ-
1 in context of SFN bioactivity, for example as an agent to stimulate Nrf2 activity 
(Malhotra et al. 2008; Beal 2009). 
DJ-1 may represent a novel target mediating bioactivity of SFN. This multi-functional 
protein is thought to be important for neuronal cell health, as mutations or absence 
of DJ-1 have been associated with PD (Clements et al. 2006; Rannikko et al. 2012).  
6.7 REDUCTION OF ER-STRESS BY SFN IN PC-12 CELLS 
The endoplasmic reticulum (ER) is an important cell organelle involved in the 
process of synthesis, folding and processing of proteins, amongst others (Loeffler G. 
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2003). DJ-1 transcription is controlled by ER-stress through the transcription factor 
XBP-1 (Duplan et al. 2013). Since DJ-1 has been connected to ER-stress, the current 
thesis assessed whether SFN could protect PC12 cells from tunicamycin-induced ER-
stress. After optimising experimental conditions for tunicamycin, a significant 
reduction of ER-stress could be observed by measuring RNA and protein levels of 
the ER-stress marker CHOP. While PC-12 cells do not display an ER-stress response 
under normal culture conditions, treatment with tunicamycin for 4 hours resulted in 
increased CHOP protein levels. 24 hour pre-treatment of PC-12 cells with SFN, which 
did not modulate CHOP expression alone, significantly reduced the increase in 
CHOP levels induced by tunicamycin. A similar effect was observed when 
tunicamycin was replaced by 6-OHDA. 
This observation is consistent with the findings of Chang Deng et al. (2012) in a similar 
experimental model. Moreover, 6h pre-treatment of PC-12 cells with 5µM SFN 
reduced the cytotoxicity generated by a 24h exposure to 80µM 6-OHDA. SFN was 
also able to reduce homocysteine-induced ER-stress in immortalised human 
hepatocytes (He et al. 2014). That study could show that TR-1 and NQO1 were 
involved in the protective effect of SFN. 
6.8 EFFICIENCY OF DJ-1 KNOCK DOWN USING SIRNA 
In order to investigate whether the ER-stress reduction induced by SFN is DJ-1 
dependent, a knock- down DJ-1 model was created using siRNA, as detailed in 
Chapter 4.2.3 (p.96). Although DJ-1 protein levels were reduced in cells affected by 
siDJ-1, consistent results could not be obtained, and immunoblotting data obtained 
using this model cannot be viewed as informative. 
DJ-1 has been reported to stabilise Nrf2 on its way to the nucleus (Clements et al. 
2006). As mentioned above, Chang Deng et al. (2012) have investigated the 
inhibition of 6-OHDA-induced ER-stress by SFN in PC-12 cells, in addition  to 
underlying mechanisms including possible involvement of Nrf2. The protective 
effects of SFN were reduced in the presence of Nrf2 siRNA, suggesting the activity 
of SFN is at least partly mediated by Nrf2. Although 5µM SFN was sufficient to 
enhance Nrf2 protein expression in the cited paper, 10µM SFN may represent an 
optimal dose to induce DJ-1 expression in our experiment model. Alternatively, a 
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higher concentration of siRNA could be used, relative to 50nM Nrf2 siRNA in the 
cited study. 
Yokota et al. (2003) investigated the relationship between DJ-1 and ER-stress in 
mouse Neruo2a cells by silencing DJ-1 using siRNA. This resulted in increased levels 
of oxidative stress-, ER stress-, and proteasome-inhibition-related cell death. We 
would have expected a similar result in our experiment model. 
While exploring the activity of SFN on DJ-1, it should be mentioned that mutations in 
Parkin and PINK1 (pten-induced putative kinase 1) have equally been associated 
with the early onset familial form of PD, (Wilhelmus et al. 2012). Parkin is an E3 
ubiquitin-protein ligase that plays a vital part in the ubiquitin-proteasome system, 
while PINK1 is important in the regulation of mitochondrial and cellular redox 
balance (Wilhelmus et al. 2012). In order to promote ubiquitination and 
degradation of Parkin substrates, a complex composed of all three proteins is 
formed (PPD complex). All three proteins are involved in mitochondrial dysfunction, 
oxidative injury and faulty functioning of the ubiquitin-proteasome system (UPS) 
(Wilhelmus et al. 2012). Including Parkin and PINK1 in further investigations of ER-
stress, in the presence or absence of DJ-1, might indicate a potential role for DJ-1 in 
the development of PD. 
6.9 REDUCING AUTOPHAGY BY USE OF CHEMICAL INHIBITORS 
Although Nrf2 is probably the most important target of SFN, other mechanisms need 
to be considered when investigating the potential protective effects of this 
molecule. To examine the importance of autophagy in the neuroprotective activity 
of SFN, autophagy inhibitors were introduced into a PC-12 cell model as described 
in Chapter 5.2.1 (p.101). By suppressing autophagy, the current thesis aimed to 
determine whether neuroprotection induced by SFN was ablated in these 
experimental conditions. 3-MA and wortmannin prevent autophagosome 
formation by inhibiting class III phosphatidylinositol 3-kinases (PI3K III), which form a 
complex with Beclin1 and other components during the process of autophagy; and 
both 3-MA and wortmannin are considered useful experimental tools (Triola 2015). 
As detailed in Chapter 5.2.1 (p.101), PC-12 cells were treated with 5µM SFN together 
with 3-MA or wortmannin for 24 hours and LC3-II protein expression was analysed. 
While SFN induced, as expected, an increase in LC3-II levels, both autophagy 
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inhibitors surprisingly either elicited no change relative to control or induced a minor 
increase in LC3-II levels. Therefor an alternative method to inhibit autophagy was 
selected, as described in Chapter 5.2.2 (p.104). 
Zhang et al. (2015) applied 3-MA to PC-12 cells in their investigation of autophagy 
as a regulator of colistin-induced apoptosis. These authors also analysed the protein 
expression of LC3-II relative to 3-MA and only observed a minor decrease in LC3-II 
expression compared to control, but a clear decrease compared to colistin or 
rapamycin was recorded. 3-MA has been utilised in several studies in cancer cells 
in conjunction with SFN; however, SFN and 3-MA were investigated in a different 
context, as these study groups did not demonstrate any immunoblotting data using 
3-MA against LC3 (Herman-Antosiewicz et al. 2006; Kanematsu et al. 2010; 
Nishikawa, Tsuno, Okaji, Sunami, et al. 2010).  
Wu et al. (2010) suggested that 3-MA should be used with caution, it may transiently 
block class III PI3K, while inhibiting class I PI3K permanently; wortmannin has been 
reported to show the opposite binding affinity. 
6.10 GENERATING ATG16L1 KO PRIMARY NEURONAL CELLS AND 
ASSESSING THE PRESENCE OF AUTOPHAGY IN AGA16L1 KO 
AND WT PNCS 
To study the role of autophagy in SFN-mediated cytoprotective effects, WT and 
Atg16L1 KO PNCs were generated (see Chapter 5.2.2, p.104).  We hypothesised that 
the loss of Atg16L1 leads to the loss of autophagy, which could serve as a suitable 
cell model to investigate the neuroprotective effects of SFN in relation to the 
autophagic pathway. Atg16L1 KO PNCs did not show any morphological 
difference to WT cells.  
By investigating the number of LC3-II punctae by immunostaining, it was 
determined that Atg16L1 KO PNCs, unlike their WT counterpart, did not show any 
enhanced autophagosome formation after SFN treatment or starvation with HBSS 
(Chapter X). Thus, autophagy was indeed suppressed in this model.  
Since Atg16L1 is associated with the development of Crohn’s disease, a type of 
inflammatory bowel disease, a number of studies in Atg16L1 mice models have 
generated different gut-related primary cells to study this condition (Stappenbeck 
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et al. 2011). However, to the best of the author’s knowledge, Atg16L1 KO PNCs have 
not yet been studied.  
6.11 NEUROPROTECTIVE EFFECTS OF SULFORAPHANE IN ATG16L1 KO 
PRIMARY NEURONAL CELLS 
H2O2-induced cell death was reduced by SFN significantly in WT PNCs, but not in 
Atg16L1 KO as detailed in Chapter 5.2.3 (p.110). PNCs were pre-treated with SFN for 
24h before H2O2 was added for 4h. Analysis via Annexin V/PI flow cytometry 
detected a significant increase in cell survival following pre-treatment with SFN 
compared to untreated cells, in WT PNCs. However, in Atg16L1 KO cells no 
significant protective effect of SFN was observed, suggesting that autophagy is 
partly involved in the observed protective effects of SFN.  
Only recently, Wang et al. (2015) demonstrated for the first time that SFN can 
protect cells from lipotoxicity through activation of autophagy, and not the Nrf2 
pathway. Umbilical vein endothelial cells (EA.hy926) were pre-treated with 20µM 
SFN for 1h followed by exposure to palmitate (600µM) for 9h, which resulted in 
reduced caspase-3 protein levels in SFN pre-treated cells compared to palmitate 
treatment alone. Although analysis of Nrf2 and HO-1 levels demonstrated a dose-
dependent induction by SFN, inhibiting the Nrf2 pathway via siRNA did not reduce 
the protective effects of SFN. It was also determined that the protective effect of 
SFN was independent of the ERK, Akt and ER-stress pathways. By blocking 
autophagy using BAF or chloroquine (both of which inhibit autophagosome-
lysosome fusion), or alternatively by silencing AMPK, SFN did not induce any 
protective effects.  Therefore SFN may protect EA.hy926 cells from palmitate-
induced lipotoxicity via AMPK-dependent autophagy. It is unusual and surprising 
that the Nrf2 pathway was not involved in meditating the protective effects of SFN, 
so these findings may be specific to EA.hy926 cells.  
In future studies of the neuroprotective effects of SFN, Nrf2 could be knocked down 
in PNCs (WT) to assess the involvement of Nrf2 in mediating SFN activity. Moreover, 
cytoprotection of SFN against toxin-induced cell death could be examined in 
relation to both pathways simultaneously by silencing Nrf2 with siRNA in Atg16L1 KO 
and WT PNCs.  
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The aim of research presented in Chapter 5.2.3 (p.110) was to assess if autophagy 
was an alternative mechanism involved in the protective effects of SFN, possibly in 
conjunction with the role of Nrf2. However, the findings of Wang et al. (2015) suggest 
that autophagy may play an even greater role in cytoprotection than so far 
established.  
6.12 FUTURE PERSPECTIVES 
Based on the data presented in this thesis, the two most intriguing observations that 
should be further investigated are the SFN/DJ-1/Nrf2/ER-stress interaction as well as 
the role of autophagy in the neuroprotective effects of SFN. 
By using a knock down DJ-1 model, the effect of this protein on the cytoprotective 
effects of SFN in ER-stress could be assessed, perhaps in conjunction with silencing 
of Nrf2. Since DJ-1, Parkin and PINK1 have all previously been associated with PD (B 
et al. 2009; Wilhelmus et al. 2012), it would be of particular interest to investigate if 
the expression of Parkin and PINK1 can also be modulated by SFN.  
Further examination into the involvement of autophagy in the neuroprotective 
effects of SFN is an exciting field with many possibilities. Autophagy is a complex 
mechanism that has not fully been established. Owing to its dual role of providing 
energy as well as removing organelles, any impairment of this sensitive system can 
have a detrimental impact. As already described, several neurodegenerative 
diseases have been linked to dysfunctional autophagy (Sanchez-Perez et al. 2012; 
Sarkar 2011). 
The Atg16L1 KO system described in this thesis warrants a more detailed assessment, 
including the effect SFN on Nrf2-regulated enzymes, which can now be studied in 
an autophagy-suppressed environment. 
In addition to investigating the mechanisms underlying the cytoprotective effects 
of SFN, SFN could be studied in human intervention studies, to attempt to correlate 
identified cellular activities of SFN with neurodegenerative disease development 
and outcome. Based on evidence from animal models, Shah & Duda (2015) have 
hypothesised that phytochemicals, such as SFN, may contribute to neuroprotection 
in PD and that adopting a plant-based diet may alter disease progression and 
provide improvement in the symptomatic of PD (Shah & Duda 2015).  
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Apart from the many reports on the beneficial effects of SFN, hormetic effects of 
ITCs  have been described (Bao et al. 2014). Low doses of ITCs may have the 
potential to be either beneficial or harmful, and as the relevant molecular 
mechanisms are not fully elucidated, these should be addressed in future research. 
However, consumption of broccoli is still considered to be a dietary intervention 
which may help to prevent many types of cancers. Several epidemiological studies 
have been performed to examine links between dietary intake of isothiocyanates 
and reduced cancer risk (Verhoeven et al. 1996; Kristal & Lampe 2002), but, to the 
author’s knowledge, no epidemiological research has been undertaken to 
investigate the association of an isothiocyanate-rich diet and neurodegenerative 
diseases.  
In conclusion, this thesis has contributed to the current understanding of the 
biological activity of SFN in neuronal cells.  However, further research is required to 
explain fully the mechanisms underlying the observed neuroprotective effects of 
SFN. Increased dietary intake of SFN-containing food sources could represent a 
simple way to reduce the risk of neurodegenerative diseases, which is of a particular 
interest in today’s increasingly aging society.  
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8 APPENDICES 
8.1 FREQUENTLY USED BUFFERS AND SOLUTIONS 
5x Loading buffer 
0.625M Tris base (Ultrapure)  3.78g 
2% SDS (Sodium Doecyl Sulphate)  1g 
10% Glcerol    5ml 
10x PBS buffer (stock solution) 
 NaCl 80g 
 KCl 2g 
 Na2HPO4 11.1g   pH 7.4 
 KH2PO4 2g     add 1L ddH2O, mix well.  
Lysis buffer (NP40)  for 500ml 
20mM Tris-EDTA/HCl pH 8 for 500ml (add 10ml of this solution) [2mM EDTA] 
150mM NaCl 4.35g 
10% Glycerol 50ml 
1% Nonidet P40 5ml 
Complete volume up to 500ml with ddH2O and MIX WELL 
PBST (Phosphate Buffered Saline Tween-20) 
PBS pH 7.4 containing 0.1% Tween 20 
Transfer Buffer  for 500ml 
 10% Bio-Rad transfer buffer 10x 50ml 
20% methanol  100ml 
70% H2O 350ml 
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REAGENTS TO 
PREPARE 
COMPONENTS 
60MM PLATE OR  
3.2X106 CELLS 
100MM PLATE OR  
8.8X106 CELLS 
PBS/PHOSPHATASE 
INHIBITOR 
10x PBS 0.4ml 0.8ml 
 Distilled water 3.4ml 6.8ml 
 Phosphatase Inhibitor  0.2ml 0.4ml 
 TOTAL REQUIRED 4.0ml 8.0ml 
1X HYPOTONIC 
BUFFER 
10x Hypotonic Buffer 25.0µl 50.0µl 
 Distilled water 225.0µl 450.0µl 
 TOTAL REQUIRED 250.0µl 500.0µl 
COMPLETE LYSIS 
BUFFER 
10mM DTT 2.5µl 5µl 
 Lysis Buffer AMI 22.25µl 44.5µl 
 Protease Inhibitor 
Cocktail 
0.25µl 0.5µl 
 TOTAL REQUIRED 25.0µl 50.0µl 
Table 8: Composition of solutions necessary for nuclear protein extraction 
The nuclear extract kit was purchased from Active Motif (Cat.No. 40010). It did 
not provide the information on concentrations of the phosphatase inhibitor, lysis 
buffer AMI or protease inhibitor cocktail. 
 
 
 
8.2 METHOD OPTIMISATION TABLES AND PROTOCOLS 
8.2.1  CELL CYCLE METHOD OPTIMISATION TABLE 
 
 
 
 
Figure 47: Cell cycle assay optimisation 
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8.2.2  ANNEXINV/PI METHOD OPTIMISATION TABLE AND GATING 
 
 
 
 
Figure 49: Flow cytometry AnnexinV/PI gating for results in Figure 28, p.85. 
SFN protects PC-12 cells from H2O2-induced cell death. 
 
Figure 48: AnnexinV/PI assay optimisation table 
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Figure 50: Flow cytometry AnnexinV/PI gating for results shown in Figure 29, p.85.  
SFN protects PC-12 cells from 6-OHDA induced cell death. 
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8.2.3  PLATING OF CELLS 
Experiment Size of plate PC-12 DIFF PC-12 SH-SY5Y 
Western Blot  6 wells 1x106/plate 20.000/well 1.5x106/plate 
MTT assay 96 wells 1x106/plate 1000/well 2x106/plate 
RNA extraction 6 wells 1,2x106/plate - 1,5x106/plate 
AV/PI 12 wells 70.000-140.000 / 
well/ml 
10.000-20.000 / 
well/ml 
150.000-300.000 / 
well/ml 
Cell cycle 6 wells 1.2x106/plate 10.000/well (12-well 
plate) 
1.5x106/plate 
JC-1 12 wells 80.000/well - - 
siRNA 96 wells 0.5x106/plate - - 
 12 wells 80.000-160.000 / 
well/ml 
- - 
 6 wells 1x106/plate - - 
Table 9: Seeding density chart 
 
 
Figure 51: Flow cytometry AnnexinV/PI gating for results in Figure 65, p.153. 
A dose responsive induction of apoptosis by SFN 
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8.2.4  JC-1 
PC-12 cells were seeded in 12 well plates at a concentration of 80.000 cells/well. On 
day 3, treatment with SFN or DMSO control is started. After 24h, the treatment media 
is replaced by H2O2 containing media and incubated for another 24h. On day 5 the 
staining with JC-1 is started. Treatment media is replaced by 400µl JC-1 at working 
concentration (2µM). The plate is then placed on a rocker for 30 mins. Then the 
media is removed and placed into allocated tubes and spun down. 50µl trypsin is 
added to the remaining cells and after a minute is joined by 250µl of media. The 
media of the previously spun down cells is removed and the 250µl media containing 
the attached cells are added. The pellet is resuspended and put into allocated 
1.5ml Eppendorf tubes, in which the samples are then read on the flow cytometer. 
Results did not show the expected shift towards the right if plotted against FL-1 on x 
and FL-2 on y axis, so the involvement of SFN in change of membrane potential 
could not be determined. However, protective effects could also be observed 
(Figure 52). 
 
 
Figure 52: JC-1 experiment  
PC-12 cells were treated with 0.01% DMSO or 2.5µM SFN for 24h. This was replaced 
by 600 or 800µM H2O2 for another 24h. After 30mins incubation with JC-1, samples 
were analysed using flow cytometry. Each bar represents the average of 2 
biological replicates. 
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8.3 ADDITIONS TO CHAPTER 3 
8.3.1  SULFORAPHANE AND CELL CYCLE IN SH-SY5Y CELLS 
SFN on cell cycle in SH-SY5Y cells. The data collected from SFN treatment on SH-
SY5Y cells presented a stronger indication of S phase arrest (Figure 53). However, as 
control samples could not be collected due to low recovery numbers, no direct 
comparison can be made. Still, looking at SFN-treated samples alone, an increase 
of percentage of cells can be seen in 10 and 20µM SFN (26.94% and 41.22%) 
compared to 2.5µM (22.92). This increase was followed by a corresponding 
decrease in G1 phase cell percentage. G2 phase did not change between SFN 
treatment samples. 
Cell cycle was also assessed in DIFF PC-12 cells, however they showed polyploidy 
and therefore could not be quantified properly. This result however confirms 
previous reports of DIFF PC-12 cells demonstrating this phenomenon, which confirms 
also on cellular level that PC-12 have indeed been differentiated (example graphs 
shown in Figure 54). 
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Figure 53: Cell cycle assay of SFN in SH-SY5Y cells. 
Cells were exposed to media alone, DMSO (0.05%) or different SFN 
concentrations (2.5µM-20µM) for 24h. The distributions of cells in different cell 
cycle stages was obtained using flow cytometry and FlowJo software (n=1). 
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8.3.2  EFFECT OF SFN ON PHASE I I  AND ANTIOXIDANT ENZYME EXPRESSION 
 
SFN on Nrf2 in nuclear protein of PC-12 cells 
 
 
Figure 55: Nrf2 expression in PC-12 cells after SFN treatment as determined 
by western blot. 
PC-12 cells were treated with DMSO (0.02%) or various concentrations of SFN 
(2.5-10µM) for 1h, 2h, 3h or 24h. Nuclear protein was collected and blots were 
imaged using Odyssey. The graph shows the trend of the individual time points 
(2h: n=2; all others: n=1). 
SFN on TR-1 gene expression in PC-12. 2h and 6h RNA samples were quantified 
with qPCR. SFN-treated samples show a fold change of up to 3 fold, as seen 
in the 6h 5µM SFN sample. These results (Figure 56) show a single biological 
replicate carried out in 3 technical replicates. 
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Figure 56: TR-1 expression in PC-12 cells after 2h or 6h SFN treatment as determined 
by qPCR. 
Cells were treated with media alone, DMSO (0.02%), or various concentrations of 
SFN (1.25-10µM) for 2h or 6h. 18S rRNA was used as housekeeping gene. Bars show 
qPCR results as fold change compared to control samples. Each bar represents a 
single biological replicate carried out in 3 technical replicates (n=1). 
 
SFN on GST gene expression in PC-12. 2h and 6h RNA samples were quantified with 
qPCR. SFN treatment samples show an increase in GST expression of up to 2-fold in 
2h and 4.5-fold in 6h samples, with the lower SFN concentrations showing the 
greatest induction (Figure 57). However, this result only shows one biological 
replicate, hence more repeats are necessary for a significant conclusion. 
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Figure 57: GST expression in PC-12 cells after 2h or 6h SFN treatment as determined 
by qPCR. 
Cells were treated with media alone, DMSO (0.02%), or various concentrations of 
SFN (1.25-10µM) for 2h or 6h. 18S rRNA was used as housekeeping gene. Bars show 
qPCR results as fold change compared to control samples. Each bar represents a 
single biological replicate carried out in 3 technical replicates (n=1). 
 
 
Figure 58: TR-1 expression in SH-SY5Y cells after 2h and 6h SFN treatment as 
determined by qPCR. 
Cells were treated with media alone, DMSO (0.02%) or various concentrations of 
SFN for 2h and 6h. 18S rRNA was used as housekeeping gene. Bars show qPCR 
results as fold change compared to vehicle control samples (media only). Each 
bar represents one biological replicate carried out in 3 technical replicates (n=1). 
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Figure 59: GST expression in SH-SY5Y cells after 2h and 6h SFN treatment as 
determined by qPCR. 
Cells were treated with media alone, DMSO (0.02%) or various concentrations of 
SFN (1.25-2.5µM) for 2h or 6h. 18S rRNA was used as housekeeping gene. Bars 
show qPCR results of 2h and 6h experiments as fold change compared to vehicle 
control samples (media only). Each bar represents one biological replicate 
carried out in 3 technical replicates (n=1). 
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8.3.3  NEUROPROTECTIVE EFFECTS OF SULFORAPHANE ON PC-12, DIFF PC-12 
AND SH-SY5Y CELLS  
Dose-dependent increase of apoptosis by SFN in PC-12 cells. The AnnexinV/PI Flow 
Cytometry results (see Figure 60) show that 1.25, 2.5, 5 and 10µM SFN increases 
apoptosis in a dose-responsive manner. From 8.16% cell death in control cells, 
1.25µM already presents 10.8% apoptotic cells, increasing to 28.11% in 10µM SFN 
samples. The cell number in “gate 1” decreased with higher concentrations of SFN 
most likely due to a higher occurrence of debris within the sample. 
 
Figure 60: Apoptosis of SFN on PC-12 cells measured by flow cytometry. 
Cells were cultured in 6-well plates (200.000 cells/well) and treated with media, 
DMSO (0.05%) or various concentrations of SFN (1.25-10µM) for 24 hours at ~70% 
confluency. Collected samples were used with the AnnexinV/PI kit and analysed 
on the flow cytometer. Each bar represents a single biological replicate of 10.000 
events. 
Cell-protective effect of SFN against H2O2-induced apoptosis in PC-12 cells. This 
graph shows two individual experiments consisting of two biological replicates each 
(see Figure 61). By plotting them individually, the in some cases great recovery of 
up to 40% can be seen more clearly. 
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Figure 61: Effect of SFN on H2O2-induced apoptosis in PC-12 cells measured by flow 
cytometry – individual experiments. 
Cells were pre-treated with either DMSO (0.025%) or 2.5µM SFN for 24h. Then these 
solutions were replaced with either serum-free media, 600µM or 800µM H2O2 for 
another 24h. The collected samples were analysed using the AnnexinV/PI kit and 
a flow cytometer. Bars are the average of 2 biological replicates with about 
10.000 events each (n=2; ±SD). 
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8.4 ADDITIONS TO CHAPTER 4 
 
Figure 8.6 Flow diagram of DJ-1 related experiments This lists the experiments planned 
to determine whether DJ-1 can influence the ability of SFN to protect PC-12 cells from 
tunicamycin-induced ER-stress.   
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8.4.1  ANALYSIS OF DJ-1 EXPRESSION AFTER TREATMENT WITH EMETINE, 
ANISOMYCIN AND CYCLOHEXIMIDE 
To investigate the increased DJ-1 levels, protein inhibitors like emetine, anisomycin 
and cycloheximide (CHX) were added to SFN treatment. All three compounds are 
commonly used to block protein synthesis through various pathways. This 
experiment has also been carried out at various time points. Figure 63 shows an 
example of the resulting western blot experiments. Interestingly, protein levels are 
increasing over time, especially in combined SFN + CHX, which suggests that either 
the amount of CHX used was not enough to inhibit protein translation, that the 
production of DJ-1 is in fact not due to an increase in translation, or that SFN itself is 
regulating the production of DJ-1 by inhibiting another protein responsible for 
degrading DJ-1. This was not investigated further. 
Figure 62: DJ-1 expression in PC-12 cells after SFN treatment as determined by 
western blot. 
Cells were treated with 0.02% DMSO (vehicle control) or different SFN 
concentrations and incubated for 2, 3, 4 or 24h. Nuclear protein was collected. 
Blots were imaged with Odyssey and data calculated from DJ-1 bands (23kDa) 
against SAM68 (68kDa). The bars represent one biological replicate. 
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Figure 63: DJ-1 expression in PC-12 cells after SFN and CHX treatment as determined 
by western blot. 
Cells were treated with 5µM SFN and/or 40µM CHX for 0, 1 or 3h. The blots were 
imaged by Odyssey and show DJ-1 bands at 22kDa and actin at 42kDa.    
8.4.2  CHOP EXPRESSION WITH SIDJ-1 
CHOP levels were observed under ER-stress conditions induced by tunicamycin and 
compared to basal levels when cells were transfected either with All* or DJ-1 siRNA. 
No difference could be observed between SFN pre-treated cells exposed to All* or 
siDJ-1. Since the knock-down of siDJ-1 was not successful, these results do not reflect 
any influence of DJ-1 in the ER-stress capabilities of SFN (Figure 64). Although these 
results were not relevant regarding siDJ-1, the findings once again demonstrate the 
capability of SFN to reduce tunicamycin-induced ER-stress in PC-12 cells (which can 
be seen in Figure 35). One biological replicate represented in the DJ-1 Figure 37 
had to be omitted due to outliers. 
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Figure 64: CHOP protein expression and recovery from tunicamycin-induced ER-
stress by SFN in presence of siDJ-1. 
PC-12 cells were treated with siDJ-1 before a 24h incubation with 5µM SFN. This 
was replaced by 1µg/ml tunicamycin for another 4h. Blots were imaged using 
Odyssey looking at CHOP (27kDa) and β-actin (42kDa) levels. The graph shows 
the quantification of CHOP after normalisation with β-actin expressed as fold 
change compared to the DMSO control. Each bar represents the average of 3 
biological replicate. **P<0.02 
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8.5 ADDITIONS TO CHAPTER 5 
8.5.1 ACTION OF SFN AND 3-MA AGAINST H2O2 INDUCED CELL DEATH 
Cell protective effects of SFN against H2O2 induced apoptosis in presence of 3-MA. 
The autophagy inhibitor 3-MA leads to more death in combination with H2O2 than 
H2O2 on its own. SFN cannot rescue as many cells from H2O2 induced apoptosis in 
the presence of 3-MA (Figure 65). However, due to the fact that the autophagic 
pathway could not be fully suppressed with 3-MA (see Figure 39, p.103), these results 
may not reflect an absence of autophagy at all. This however led to a different 
approach, using Atg16L1-KO PNCs instead. 
 
Figure 65: Effect of SFN on H2O2-induced apoptosis in PC-12 cells in the presence or 
absence of 3-MA, measured by flow cytometry. 
Cells were pre-treated with either DMSO (0.025%) or 2.5µM SFN and/or 5mM 3-MA 
for 24h. Then, the treatment solution was replaced with either serum-free media 
alone or 600µM H2O2 for another 24h. The collected samples were analysed using 
the AnnexinV/PI kit and run on a flow cytometer. Results show the percentage of 
viable cells. Each bar represents a single biological replicate with about 10.000 
events each (n=1). 
 
8.5.2  GATING OF AV/PI EXPERIMENTS OF PNCS 
Flow cytometry gate settings. As usual, events were gated to remove any debris 
from further calculation. Next, a graph plotting height and area of the forward 
scatter was used to gate only single cells. A forward and side scanner would 
usually be used as it is to set the gating for apoptosis. However, there was a clear 
differentiation in two cell groups visible, which were therefore gated separately as 
well as together (Figure 66Figure 67Figure 68).  
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Figure 66: General Gating – splitting into top and bottom cells 
 
 
Figure 67: AV/PI graphs of top gated cells. 
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Figure 68: AV/PI graphs of top gated cells 
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8.5.3  GENOTYPING 
 
Figure 69: Atg16L1 genotyping of mice by PCR. Using end-point PCR and gel 
electrophoresis, Atg16L1 alleles were genotyped as wild-type (+/+ or +/-) and 
knock-out (-/-). 
 
8.5.4  COATING PROTOCOL OF PLATES FOR PNCS 
Poly ornithine Coating. A solution of 15µg/ml poly-ornithine solution was prepared. 
The wells were covered with it (1ml for 12well plate) and left in the incubator at 37°C 
over night. 
Poly-D-lysine. A working solution of 50µg/ml was prepared. The surface of the 
culture vessel was covered (400µl for 12well plate) and then incubated at room 
temperature for 1h. The plates were thoroughly rinsed 3x with distilled water, as 
excess poly-D-lysine can be toxic to the cells. The coated plates are left uncovered 
under the hood until the wells have dried. Plates were used the next day, but can 
be stored at 4°C for one week when wrapped tightly in parafilm. 
Before the cells are seeded, the plates are washed twice with sterile water and 
once with sterile filtered PBS. Then the PBS is replaced by DMEM/F12 +10% FBS (v/v) 
and left in the incubator at 37°C for 2h before cells are plated. 
